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Summary  
Glucose transport and metabolism in polycystic kidney disease 
 
Polycystic kidney disease (PKD) is one of the most common inherited disorders, being the fourth 
leading cause of kidney failure in humans. PKD is characterized by the formation of multiple cysts in 
the kidney. The expansion and proliferation of cysts play a key role in reducing kidney function and 
leading to chronic renal failure. There are two rat models of PKD: Han:SPRD rats which 
phenotypically resemble human autosomal dominant polycystic kidney disease (ADPKD), and PCK 
rats which are an orthologous model of autosomal recessive polycystic kidney disease (ARPKD). 
Han:SPRD develop cortical cysts which originate from proximal tubules of the nephrons, whereas PCK 
develop medullary cysts which originate from the collecting duct. 
The aim of this thesis was to examine whether the transport and the metabolism of glucose in the 
kidney play a pathogenic role in cyst proliferation and expansion in these two rat models of PKD. We 
hypothesized that the generation of an osmotic diuresis by inhibition of sodium-glucose 
cotransporters (SGLT) in the proximal tubules will force the fluid transport from cysts to the tubular 
lumen, thereby reducing cyst expansion and improving the decline in renal function. Furthermore, 
based on the knowledge of an increased demand of glucose by aerobic glycolysis in proliferating 
epithelial cells in PKD (Warburg effect) we selectively blocked glucose metabolism with the glucose 
analog 2-deoxyglucose (2DG) to test its beneficial effect in PKD. 
We first tested the dual SGLT inhibitor phlorizin in Han:SPRD rats and found a significant positive 
effect, i.e. phlorizin ameliorated the cyst expansion and improved the decline in renal function and 
reduced albuminuria. We then tested the selective SGLT2 inhibitor dapagliflozin (DAPA) in Han:SPRD 
rats and found that DAPA did not reduce cyst expansion but had a slight positive effect on renal 
function and also reduced albuminuria. In contrast, DAPA unexpectedly increased cyst expansion and 
accelerated the functional decline of renal function and increased albuminuria in PCK rats, 
presumably because of a strong osmotic effect in the collecting duct. 
We then investigated the energy metabolism in cystic tissues of Han:SPRD rats and confirmed the 
upregulation of genes involved in glycolysis and the downregulation of genes involved in 
gluconeogenesis, thus demonstrating that the Warburg effect is present in the cystic kidneys of 
Han:SPRD rats. When using 2DG to block glycolysis we found an important reduction of cyst growth 
and a slower decline of renal function and less albuminuria. 
Altogether our experimental studies in two different rat models of PKD show that glucose transport 
and metabolism play an important role for cyst growth and expansion. This sets the basis for using 
these potential targets in the future treatment of PKD. 
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Zusammenfassung  
Transport und Metabolismus von Glukose bei polyzystischer Nierenkrankheit 
 
Die polyzystische Nierenerkrankung (PKD) ist eine der häufigsten genetisch bedingten Erkrankungen 
und ist der vierthäufigste Grund für das chronische Nierenversagen beim Menschen. PKD 
charakterisiert sich durch die Bildung von multiplen Zysten in der Niere. Die Expansion und 
Proliferation der Zysten spielen eine entscheidende Rolle bei der Abnahme der Nierenfunktion und 
führen zu Nierenversagen. Es gibt zwei PKD-Rattenmodelle: Han:SPRD Ratten, welche phänotypisch 
der menschlichen autosomal dominanten polyzystischen Nierenerkrankung (ADPKD) ähneln, und PCK 
Ratten, welche ein orthologes Modell der autosomal rezessiven polyzystischen Nierenerkrankung 
(ARPKD) sind. Han:SPRD entwickeln kortikale Zysten, welche im proximalen Tubulus der Nephronen 
entstehen, während PCK medulläre Zysten entwickeln, die im Sammelrohr entstehen. 
 
Das Ziel dieser Arbeit war es, herauszufinden, ob in diesen zwei PKD-Rattenmodellen der 
Glukosetransport und –metabolismus in der Niere eine pathogene Rolle bei der Zystenproliferation 
und –expansion spielt. Wir stellten die Hypothese auf, dass die Erzeugung einer osmotischen Diurese 
durch die Inhibition der Natrium-Glukose Cotransporter (SGLT) in den proximalen Tubuli, den 
Flüssigkeitstransport von den Zysten in das tubuläre Lumen erzwingt und somit die Zystenexpansion 
reduziert und den Nierenfunktionsabfall verbessert. Ausserdem, basierend auf dem Wissen, dass es 
eine erhöhte Glukosenachfrage durch anärobe Glykolyse in proliferierenden Epithelzellen in PKD gibt 
(Warburg-Effekt), blockierten wir selektiv den Glukosemetabolismus mit dem Glukoseanalogon 2-
Deoxyglucose (2DG), um seine vorteilhaften Effekte in PKD zu testen. 
 
Zuerst testeten wir den dualen SGLT Inhibitor Phlorizin in Han:SPRD Ratten und fanden einen 
signifikanten positiven Effekt, z.B. verbesserte Phlorizin die Zystenexpansion, den 
Nierenfunktionsabfall und die Albuminurie. Dann testeten wir den selektiven SGLT2 Inhibitor 
Dapagliflozin (DAPA) in Han:SPRD Ratten und fanden, dass DAPA die Zystenexpansion nicht 
verbesserte, aber einen leicht positiven Effekt auf den Nierenfunktionsabfall und die Albuminurie 
aufwies. In der PCK Ratte bewirkte DAPA unerwarteter Weise eine signifikante Erhöhung des 
Zystenvolumens, und verschlechterte den Nierenfunktionsabfall und die Albuminurie, vermutlich 
wegen dem starken osmotischen Effekt im Sammelrohr. 
 
Wir untersuchten dann den Energiemetabolismus im zystischen Nierengewebe von Han:SPR Ratten. 
Wir fanden eine Hochregulation von Genen, welche in der Glykolyse involviert sind, und eine 
Herunterregulation von Genen, welche in der Glukoneogenese involviert sind. Dies demonstriert, 
dass der Warburg-Effekt in zystischem Gewebe von Han:SPRD präsent ist. Bei Behandlung mit 2DG, 
um die Glykolyse zu blockieren, fanden wir eine wesentliche Reduktion des Zystenwachstums und 
einen langsameren Nierenfunktionsabfall und weniger Albuminurie. 
 
Unsere Studien in zwei verschiedenen PKD-Rattenmodellen zeigen auf, dass Glukosetransport und –
metabolismus für das Zystenwachstum und die Zystenexpansion sehr wichtig sind. Dies bildet die 
Basis, um diese Vorgänge als potenzielle Ziele für zukünftige PKD Behandlungen weiter zu 
entwickeln. 
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General introduction 
 
Polycystic kidney disease (PKD) is a common genetic renal syndrome that may lead to end-
stage renal disease (ESRD) in children and adults. PKD is characterized by the accumulation 
of fluid filled cysts in the kidneys and other organs. Cysts originate from epithelial cells in the 
nephron and are characterized by a single layer of cells with an increased rate of 
proliferation. 
PKD patients present with massively enlarged kidneys with cysts of variable size, ranging 
from around 40 µm to several centimeters in diameter. The PKDs are classified among the 
ciliopathies, since primary cilia play an important pathogenic role in the disease, expressing 
the mutated proteins involved in the various forms of PKD (PC1, PC2 and fibrocystin) (1, 2). 
PKD can be subdivided in two major forms: autosomal dominant polycystic kidney disease 
(ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). 
Autosomal dominant polycystic kidney disease 
ADPKD is the most common hereditary cystic kidney disease and one of the most common 
hereditary disorders in humans. It has a prevalence of 1:400 to 1:1000. The disease 
manifests typically around the fourth decade of life, with ESRD occurring in 50% of the cases 
at the age of 60 years and in 75% at the age of 70 years. However, ADPKD already starts in 
children. The age adjusted male/female sex ratio is 1.2-1.3 (3). 
Most patients (85%) are affected by the most severe form, caused by mutations in the PKD1 
gene which is located on chromosome 16p13.3, causing a defective polycystin-1 protein. 
Mutations in the PKD2 gene, located on chromosome 4q21-23, cause a defective polycystin-
2 protein that leads to ADPKD in 15% of all cases of ADPKD (4, 5). 
Figure 1.1: ADPKD progression. Image extracted from Happé H, Peters D.J.M. Translational research in 
ADPKD: lessons from animal models. Nature Reviews Nephrology 2014 (10): 587–601 
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ADPKD is characterized by progressive development and expansion of fluid-filled cysts in 
tiny segments of the nephron (Figure 1.1). The kidney gets progressively deformed by the 
cyst expansion within the renal cortex. Cyst progression leads to kidney failure by 
compression of the healthy renal parenchyma. Among the extrarenal manifestations cysts in 
the liver, pancreas and ovaries are well known and frequent. Intracranial aneurysms are also 
associated with ADPKD and can lead to cerebral hemorrhage when rupturing (6, 7). Thus, 
ADPKD can be considered a systemic disease. 
Autosomal recessive polycystic kidney disease 
ARPKD is 20 times less common than the autosomal dominant form. Considered a rare 
ciliopathy, its incidence rate is 1:20000. Nevertheless, it is one of the most important 
nephropathies in neonates and children (8). 
The gene affected, PKHD1, is located in chromosome 6p21.1-p12 (9). Mutations in PKHD1 
lead to malformations on the fibrocystin (also termed polyductin) protein, a transmembrane 
protein present on collecting ducts in the kidney and biliary ducts in the liver (10). At the 
ultrastructural level this protein localizes to the primary cilia membrane and centrosomes in 
renal epithelial cells. Fibrocystin function is associated with terminal differentiation of the 
collecting ducts and the maintaining of normal tubular architecture of renal and biliary tubules 
(11, 12). 
Fibrocystin mutations lead to a non-obstructive fusiform dilation of the collecting ducts. The 
tubular dilation causes kidney expansion but the reniform shape of the kidney is maintained 
(13). ARPKD may lead to premature death, mainly because of severe hypertension and 
kidney failure. Patients with ARPKD also have congenital hepatic fibrosis and portal 
hypertension which is caused by cyst dilation of the biliary ducts. 
The PKD proteins: fibrocystin and polycystins 
 
Polycystins 
The proteins which are encoded by the PKD1 and PKD2 genes are termed polycystin-1 and 
polycystin-2, respectively. This family of proteins plays important roles in many biological 
processes including, mechanosensation, fertilization and ion transport across membranes. 
Polycystin-1 (PC1) is an integral membrane protein which is found in primary cilia, 
cytoplasmic vesicles and plasma membranes. It contains 11 transmembrane-spanning 
domains, a large extracellular N-terminal domain and a short cytosolic C-terminal domain 
(Figure 1.2). The extracellular domain contains several other domains such as leucine-rich 
repeats (LRRs), a C-type lectin domain, a low density lipoprotein class A repeat (LDL-A) 
region, multiple Ig-like domains and PKD domains. PC1 has a molecular weight of about 
500’000 Da, with 4303 amino acids. When PC1 is not bound to PC2, the C-terminal cytosolic 
domain stably binds and activates heterotrimeric G-proteins (14, 15). 
 
Polycystin-2 (PC2), encoded by the PKD2 gene, is also a transmembrane protein. It is 
composed by 968 amino acids. PC2 has 6 transmembrane-spanning domains and both N- 
and C-terminal cytoplasmic domains (Figure 1.2). It is also a member of the transient 
receptor potential (TRP) ion-channel family. PC2 works as a nonselective channel for Ca2+, 
10
Na+, and K+. PC2 also localizes to primary cilia, centrosomes and plasma membranes, but is 
mainly found in the endoplasmic reticulum (ER). 
PC1 and PC2 form a complex trough their C-terminal domains. Many other proteins interact 
with this complex. When PC1 and PC2 interact, the PC1 activation of G proteins is strongly 
decreased (16). The activation of the complex by a mechanical stimulus leads to 
conformational changes that trigger the PC1-mediated G protein signaling and the PC2 
calcium channel activity (17). 
Figure 1.2: Polycystin structure. Graph is from Torres VE, Harris PC. Autosomal dominant polycystic kidney 
disease: the last 3 years. Kidney Int. 2009 Jul;76(2):149-68 
 
Fibrocystin/polyductin 
The protein encoded by the PKHD1 gene is termed fibrocystin or polyductin (FPC). It is 
composed by 4074 amino acids. FPC is a membrane protein with a large extracellular 
domain (more than 3800 amino acids), a unique transmembrane segment and a short C-
terminal cytosolic tail that includes phosphorylation sites for cAMP/cGMP (possibly important 
for its function). 
FPC is localized to the plasma membrane and the primary cilium of epithelial cells from the 
collecting duct (18, 19). Its exact function remains unclear, however it is known that FPC 
interacts with PC2 and modulates renal tubular formation (20). 
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Pathways involved in PKD progression 
 
As stated above, one of the most important locations of polycystins is the primary cilium. In 
the kidney, primary cilia play a sensory role in response to urine flow. The PC1-PC2 complex 
localized on the base of cilia translates the mechanical stimulation into calcium influx trough 
PC2-channels. The increased concentration of calcium in the cell is followed by a calcium-
induced calcium release from intracellular IP3-dependent stores (21). Intracellular calcium 
regulates the cAMP level in the cell by inhibition of adenylyl cyclase 6 (AC-VI), which is 
responsible for cAMP production; and by stimulation of phosphodiesterases (PDE) which 
degrade cAMP to AMP. Conversely, depletion of calcium in the endoplasmic reticulum (ER) 
results in the translocation of a calcium sensor to the ER membrane: the stromal interaction 
molecule 1 (STIM1). This sensor regulates several store-operated channels and AC-VI. 
STIM1-induced AC-VI activity increases cAMP levels in the cytosol. This pathway is known 
as store-operated cAMP signalling (SOcAMPS)(22). 
Because of mutations in the PKD1 or PKD2 genes, PC1 or PC2 are malformed and 
dysregulate (i.e. increase) the production of cAMP. On the other hand, AC-VI is known to 
form a complex on the basal membrane with several proteins, including the vasopressin type 
2 receptor (V2R). Vasopressin is one of the main hormonal modulators of AC-VI function in 
the collecting duct. Vasopressin is mainly regulated by plasma osmolality and was found to 
be elevated in hypertensive ADPKD patients (23). Vasopressin stimulates the production of 
cAMP via AC-VI (24). Intracellular calcium levels are not enough to inhibit the activity of AC-
VI and cAMP is accumulated via SOcAMPS and V2R.  
The abnormal accumulation of cAMP leads to the activation of protein kinase A (PKA). PKA 
plays an important regulatory role in many processes in the cell, such as glycogenesis, 
gluconeogenesis and lipid metabolism. PKA also phosphorylates several transepithelial fluid 
transport proteins such as aquaporin 2 (AQP2) and epithelial ion channels including CFTR 
(25). In addition, PKA stimulates the PC2 channels on the ER and leads to the release of 
calcium from intracellular stores (26). The reduction of these calcium stores triggers the 
translocation of STIM1 to the plasma membrane and the consequent activation of AC-VI (27) 
(Figure 1.3). 
PKA is implicated in most of the processes involved in PKD progression, from cyst 
proliferation (activating transcription factors via MAPK/ERK signaling) to the fluid secretion 
(directly increasing CFTR activity). In PKD patients, the increased activity of PKA stimulates 
the extracellular signal-regulated kinases (ERK) via MEK, B-Raf, Ras, and Src (28). 
Phosphorylation of ERK leads to the inhibition of tuberous sclerosis complex proteins 
(TSC1/2) directly and indirectly (via LKB1, which inhibits the activity of AMPK) (3, 29). AMPK 
has been related with a tonic inhibition of CFTR and its reduction seems to increase fluid 
secretion (30). ERK also causes activation of transcription factors, both directly and indirectly 
(via ribosomal S6 kinase [RSK]), stimulating cell growth, proliferation and de-differentiation in 
affected cells (Figure 1.3). In normal conditions, TSC1/2 are found in a complex with Rheb, 
GDP and mTOR, binding to the cytosolic C-terminal end of PC1. The complex maintains a 
tonic inhibition over Rheb (31, 32). When PC-1 is absent, TSC2 is phosphorylated, triggering 
a further activation of Rheb and mTORC1 complex (33, 34). Activated mTORC1 boosts 
aerobic glycolysis, stimulates ATP synthesis and inhibits AMPK activity together with ERK, 
which increases mTOR signaling in a positive feedback loop (27, 29) (Figure 1.3). 
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Figure 1.3: Pathways of up- or downregulated molecules in polycystic kidney disease and potential drug targets. 
Figure is from Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney 
disease. J Am Soc Nephrol. 2014, 25: 18–32. 
It is well known that mTOR regulates the balance between cell growth and autophagy. In 
favorable conditions, activation of mTOR leads the protein synthesis and growth (34, 35). In 
PKD cells, activation of mTOR stimulates cell growth and promotes cyst expansion. 
 
Rat models for PKD 
 
There are numerous animal models of PKD (mice, rats, cats) which can be either 
orthologous to the human disease (i.e. with mutations in PKD1 or PKD2 or PKHD1) or non-
orthologous (i.e. involving genes which are different from PKD1, PKD2 and PKHD1). The 
most commonly studied mouse models of PKD include the cpk, bpk, orpk, pck, pcy and 
Pkd2ws25/- strains. The most commonly studied rat strains include the PCK and the 
Han:SPRD rats. All these models have strengths and limitations, and none of them is both 
genetically orthologous and reproduces the human phenotype of PKD (36, 37). 
Han:SPRD rats 
The Han:SPRD (Cy) rat strain was described by Kaspareit-Rittinghausen et al in 1989 as a 
spontaneous mutation of Sprague-Dawley rats and the original colony was established in 
Hanover, Germany (38). Despite of being a non-orthologous model, Han:SPRD rats are used 
as a model of ADPKD because it reproduces the typical phenotype of human ADPKD. 
Han:SPRD kidneys are characterized by formation of numerous cyst from proximal tubules. 
The disease is caused by a point mutation of the Pkdr1 (ANKS6) gene. Currently, new 
studies found that mutations in human ANKS6 are related with a nephronophthisis-like 
phenotype (39). 
Two different genotypes show renal cysts. The homozygous genotype (Cy/Cy) has a rapid 
disease progression with marked cystic dilation in all tubular segments. Cysts are less 
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pronounced in the inner medulla. The disease leads to early death in 3-weeks (40). The 
heterozygotes (Cy/+) develop a slower disease with a life span of less than 1 year in males 
and around 2 years in females. The disease progression in Cy/+ is more severe in males 
than females. Among others, a factor that can explain the increased severity in males are 
androgens. These hormones stimulates the disease progression via androgen receptors with 
the activation of MAPK pathways in males (41). 
The phenotype in heterozygous Cy/+ is characterized by cyst proliferation from proximal 
tubules mainly from juxtamedullary nephrons. Some areas of the affected proximal tubules 
show inmature cellular phenotype with loss of epithelial differentiation and variability in the 
microvilli (42). Interstitial fibrosis and an increase in inflammatory cells are also characteristic 
in Cy/+ rats. No extrarenal manifestations have been observed in this model (42, 43). 
PCK Rats 
The PCK strain was also isolated from a Sprague-Dawley colony by Katsuyama et al in 2000 
(44). The disease is originated in the Pkhd1 gene, orthologous to the gene responsible of 
human ARPKD. However, it has a milder phenotype than Han:SPRD rat with several 
phenotypical features of ADPKD. In contrast with Han:SPRD animals, in PCK rats the cysts 
are originated by dilation of collecting ducts in the outer medulla. The disease leads to death 
approximately at 1.5 years. Interstitial fibrosis and inflammation are frequent after 
approximately 1 month. A common extrarenal manifestation of this phenotype is the cyst 
formation in liver and pancreas. In liver, dilated intrahepatic bile ducts lead to fibrotic cysts in 
later stages (37, 40). 
 
Current treatments and novel therapies for PKD 
 
Current treatments in PKD are focused on treating the symptoms derived from complications 
of the disease. Among others, current therapies include blood pressure control, treatments 
for anemia or hyperlipidemia, dietary supplementation, and reduced sodium and protein 
intake (45-47). Nephrectomy and transplantation are the choices in patient who reach end 
stage renal disease (ESRD). 
The work carried out to identify the cellular mechanisms that are involved in the cyst 
expansion and proliferation has resulted in the discovery of novel targets. New animal 
models have allowed the development of many preclinical studies to test potential therapies. 
The major cause of cAMP accumulation in the cell is the activity of AC-VI. It is know that 
vasopressin, through the action of V2R, increases AC-VI activity. Thus, V2R antagonists 
become crucially important as potential drugs. Mozavaptan (OPC-31260) and more recently 
tolvaptan (OPC-41061) have been used in mouse and rat models of PKD. Recently, clinical 
trials in phase II and III have been completed using tolvaptan in PKD patients (NCT01214421 
and NCT02160145). OPC-41061 effectively ameliorates the cyst progression, slows the 
increase in kidney volume growth, and improves the decline in kidney function. As side-
effects, tolvaptan causes dose-dependent aquaresis (48). 
High water intake (HWI) was proposed as another way to reduce the action of vasopressin in 
the cAMP generation. HWI was beneficial in PCK rats but did not reduce the severity of 
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disease in Han:SPRD rats (49). The applicability for ADPKD patients is still controversial and 
should be restricted to non-severe patients (eGFR>60) (24, 50). 
AC-VI can also be inhibited by blocking the somatostatin receptors (SSTR), reducing the 
levels of cAMP in cytoplasm. Somatostatin analogues (lanreotide and octreotide) were 
shown to have beneficial effects on kidney volume increase and slowed the cyst progression 
in patients (51). Octreotide and lanreotide are well tolerated and can be administered via 
intramuscular injections on the hip. The most common adverse reaction is diarrhea. 
The mTOR pathway is involved in several human diseases including diabetes mellitus, 
cancer and PKD. Inhibitors of mTOR like rapamycin (sirolimus) and everolimus were quite 
promising for the treatment of PKD, reducing cyst growth and ameliorating kidney function by 
preventing epithelial cell proliferation in mice and rats (52, 53). However, when clinical trials 
were conducted with both sirolimus and everolimus in PKD patients, no beneficial effects 
were found (54, 55). 
Many other potential targets have been subjected to preclinical and clinical testing. Triptolide, 
Scr inhibitors, a TNF antagonist, CFTR inhibitors, metformin or CDK inhibitors among others 
demonstrated a variable efficacy to slow down the disease progression but none of them 
resulted in a real cure (56-59). 
 
SGLT inhibitors 
The kidney plays a key role in glucose homeostasis in the body. The sodium-glucose 
cotransporters (SGLT) are a family of membrane proteins responsible for the transport of 
glucose from the lumen into the epithelial cells. The SGLTs which have been found in the 
kidney are SGLT1 and SGLT2, managing transport of glucose and sodium across the 
proximal tubular epithelium (60). SGLT1 transports two molecules of glucose with every one 
sodium whereas SGLT2 transports only one glucose per sodium (61). 
Figure 1.4: Inmunostaining for sodium-glucose cotransporters in the rat kidney. A) SGLT1 located on the brush 
border of S3 segment of proximal tubules. B) SGLT2 located on segments S1 and S2 of proximal tubules. 
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SGLT1, located in the third segment (S3) of the proximal renal tubule, is a low-capacity, high-
affinity sodium-glucose cotransporter, responsible for 10% of glucose reabsorption. SGLT2 in 
contrast is located in the S1 segment and is a high-capacity, low-affinity transporter, 
mediating around 90% of glucose reabsorption in the kidney (62, 63) (Figure 1.5). 
 
Figure 1.5: Sodium-glucose cotransporters (SGLT1/2) are located on the apical side in the proximal tubules of 
the kidney. SGLTs and GLUTs form transport pairs (SGLT1/GLUT1 and SGLT2/GLUT2) who manage glucose 
reabsorption in the different segments of proximal tubules. 
 
Due to its main role in glucose reabsorption in the kidney, SGLTs have been a potential 
target for diabetes mellitus treatments. By blocking SGLT actions, SGLT inhibitors strongly 
inhibit glucose reabsorption form the lumen of the proximal tubules which leads to glucosuria 
and osmotic diuresis. 
 
Phlorizin, a non selective SGLT inhibitor extracted from the root bark of the apple tree, is 
known to lower glucose reabsorption (64). Phlorizin is poorly absorbed from the 
gastrointestinal tract and should be administered via subcutaneous injections. In addition to 
inhibiting SGLT2, phlorizin also inhibits SGLT1 which is mainly located in the gastrointestinal 
tract, leading to glucose and galactose malabsorption, dehydration, and diarrhea (65). Thus, 
its potential use in the treatment of diabetics is limited. Several studies with dapagliflozin 
(DAPA), a novel selective SGLT2 inhibitor, demonstrated excellent efficacy in diabetes 
mellitus type 2 patients correcting hyperglycemia and reducing hemoglobin A1c effectively 
(66). In contrast to phlorizin, DAPA can be administered orally and is well tolerated in 
humans. Many other SGLT inhibitors, both selective and non-selective, are being developed 
for the treatment of type 2 diabetics (67, 68). 
 
The balance between fluid secretion and reabsorption into the lumen of cyst is slightly 
skewed in the direction of secretion (23). By increasing glucose concentration in the lumen of 
tubules, SGLT inhibitors may produce an osmotic gradient from adjacent cyst to the epithelial 
lumen, counteracting the cyst expansion by fluid secretion. 
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Glucose metabolism and 2-deoxyglucose 
A study by Rowe et al. has shown that aerobic glycolysis was elevated in the absence of 
PC1 in a mouse model of ADPKD and also in kidney tissues from patients with ADPKD (29). 
It is well known that cancer cell and proliferative tissues increase their glucose intake and, 
unlike normal tissue, use fermentation to decompose glucose even in the presence of 
enough oxygen (aerobic glycolysis)(69). This phenomenon was named Warburg effect 
(Figure 1.6). 
Figure 1.6: Metabolic alterations in PKD kidneys by Warburg effect. On the left, normal kidney cells metabolize 
glucose into ATP via tri-carboxylic acid (TCA) cycle. On the right, cystic kidney stimulates generation of lactate via 
aerobic glylcolysis (Warburg effect). From Priolo C, Henske EP. Metabolic reprogramming in polycystic kidney 
disease. Nature Medicine. 2013. 19, 407–409 
 
The increased demand of glucose by proliferative cells may be used therapeutically by target 
cystic tissue. A possible way to use this target is with analogs of glucose that cannot be 
metabolized, thus blocking the glycolysis pathway and reducing considerably cyst 
proliferation. Previous studies with 2-deoxyglucose (2DG) found that cyst growth could be 
inhibited in mouse models of PKD (29, 70). So far, there were no experiments conducted in 
rat models with a slower disease progression. 
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Aims of this thesis 
 
Despite the fact that many different therapies were tested, there is currently no effective 
treatment for such a complex disease as PKD. Glucose transport and metabolism in the 
kidney has emerged as an important factor that promotes PKD disease. Targeting glucose 
transport and metabolism may thus represent a promising strategy to treat PKD. 
We hypothesized that by generating the osmotic diuresis and glycosuria, SGLT inhibitors 
produce an osmotic gradient from the lumen of cysts to the renal tubules, reducing the cyst 
expansion and ameliorating the disease progression in PKD rat models. 
We also hypothesized that to reduce glucose metabolism in cystic cells, the glucose 
analogue 2-deoxy-glucose may have beneficial effects in rat models of PKD. 
 
Thesis outline 
 
Chapter 2 describes a study of the effects of the SGLT inhibitor phlorizin in the Han:SPRD 
rat model of ADPKD. Phlorizin effectively reduced kidney volume and ameliorated the 
decline in kidney function. Furthermore, phlorizin had a beneficial effect on proliferation. 
Following the promising results from Chapter 2, a novel, selective SGLT2 inhibitor, 
dapagliflozin (DAPA), was tested on Han:SPRD rats (Chapter 3). DAPA caused renal 
glycosuria and improved the renal function in Han:SPRD rats but, unexpectedly, had no 
effect on the cyst progression or proliferation. In Chapter 4, we tested dapagliflozin in an 
ARPKD rat model, the PCK rat. DAPA caused a significant expansion of cysts in PCK and 
led to a reduction in kidney function and increased albuminuria. The novel technique of high 
resolution ultrasound imaging was used in Chapter 4 and is described in greater detail in 
Chapter 5. Changing the way to approach the disease, Chapter 6 is focused on the 
inhibition of aerobic glycolysis by 2-deoxyglucose (2DG) in Han:SPRD rats. 2DG reduced 
considerably the activity of enzymes involve on glucose degradation and ameliorated the 
cyst expansion. Treated rats displayed improved kidney function and a reduced cyst 
epithelial cell proliferation. Chapter 7 is focused on the eGFR prediction in a Swiss ADPKD 
patient cohort with up to 10 years of follow-up. Finally, the results exposed in the individual 
chapters of this thesis are concluded with a summarizing discussion in Chapter 8. 
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Renal tubular epithelial cell proliferation and transepithelial
cyst fluid secretion are key features in the progression of
polycystic kidney disease (PKD). As the role of the apical renal
sodium–glucose cotransporters in these processes is not
known, we tested whether phlorizin inhibits cyst growth and
delays renal disease progression in a rat model of PKD.
Glycosuria was induced by subcutaneous injection of
phlorizin in male heterozygous (Cy/ þ ) and wild-type
Han:SPRD rats. Phlorizin induced immediate and sustained
glycosuria and osmotic diuresis in these rats. Cy/ þ rats
treated with phlorizin for 5 weeks showed a significant
increase in creatinine clearance, a lower 2-kidneys/body
weight ratio, a lower renal cyst index, and reduced urinary
albumin excretion as compared with vehicle-treated Cy/ þ
rats. Measurement of Ki67 staining found significantly lower
cell proliferation in dilated tubules and cysts of Cy/ þ rats
treated with phlorizin, as well as a marked inhibition of the
activated MAP kinase pathway. In contrast, the mTOR
pathway remained unaltered. Phlorizin dose dependently
inhibited MAP kinase in cultured tubular epithelial cells from
Cy/ þ rats. Thus, long-term treatment with phlorizin
significantly inhibits cystic disease progression in a rat model
of PKD. Hence, induction of glycosuria and osmotic diuresis
(glycuresis) by renal sodium–glucose cotransporters inhibition
could have a therapeutic effect in polycystic kidney disease.
Kidney International (2013) 84, 962–968; doi:10.1038/ki.2013.199;
published online 29 May 2013
KEYWORDS: polycystic; phlorizin; rat; sodium–glucose cotransport
Autosomal dominant polycystic kidney disease (ADPKD) is
characterized by the development of innumerable renal cysts
which originate from the tubular epithelium of various
nephron segments.1 Cystogenesis in ADPKD reflects epithelial
dedifferentiation, increased proliferation, and abnormal fluid
secretion.2 The compression of healthy adjacent parenchyma
by the expanding cysts leads to progressive renal failure, with
more than 50% of the patients reaching end-stage renal
disease during their lifetime.3 Insights into the pathophysio-
logical processes that govern cyst development led to a
growing number of drug candidates in ADPKD. In particular,
several drugs targeting epithelial cell proliferation or the
transport processes that contribute to intracystic fluid
secretion have recently been proposed. These drugs
include mammalian target of rapamycin (mTOR) inhibitors,
somatostatin, and vasopressin type 2 receptor antagonists.4,5
The dihydrochalcone phlorizin is a natural product and
dietary constituent which is found in a number of fruit trees.6
For decades, it has been extensively used as a tool for
physiological research. Phlorizin’s principal pharmacological
action is to produce renal glycosuria and—to a lesser degree—
to block intestinal glucose absorption through inhibition of the
Naþ –glucose cotransporters (SGLTs) located apically in the
proximal tubules of the kidneys and the small intestinal mucosa.
The administration of phlorizin to experimental animal models
results in profound inhibition of the renal SGLTs in renal
proximal tubules, resulting in marked glycosuria.6
To the best of our knowledge, the role of SGLTs in the
pathogenesis of polycystic kidney disease (PKD) has never
been examined. We hypothesized that induction of glycosuria
and osmotic diuresis by inhibiting renal SGLTs could slow
cystogenesis and renal disease progression. To test this
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hypothesis, we treated heterozygous (Cy/ þ ) Han:SPRD rats
with phlorizin and investigated the effects of chronic glycuresis
on parameters of renal function and cystogenesis. Our data
demonstrate that phlorizin effectively retarded renal functional
loss and cyst volume growth in this rat model of PKD.
RESULTS
Phlorizin treatment induces glycosuria and osmotic diuresis
in Han:SPRD rats
Treatment of 5-week-old male heterozygous (Cy/ þ ) and
wild-type ( þ / þ ) Han:SPRD rats with phlorizin (400 mg/
kg/day subcutaneous in propylene glycol) induced an
immediate and sustained glycosuria. The glycosuria was
accompanied by a threefold increase in urine output,
reflecting the increased osmolar excretion (Table 1;
Figure 1a and b). In contrast, Cy/ þ and þ / þ rats injected
with the vehicle (propylene glycol) did not develop
glycosuria. Plasma glucose levels did not change in response
to phlorizin (Table 1). Despite the massive polyuria, plasma
osmolality and plasma sodium and chloride concentrations
were stable in Cy/ þ rats at days 17 and 35 of treatment,
suggesting that the animals adequately compensated for the
osmotic diuresis and did not get dehydrated. Of note,
phlorizin-treated Cy/ þ rats displayed a slightly enhanced
urinary sodium and chloride excretion rate compared with
vehicle-treated rats, as well as a 6.7% weight difference at the
end of the treatment period (Table 1).
Effect of phlorizin treatment on renal function
After 5 weeks of treatment with phlorizin, the plasma creatinine
was 28% lower in male Cy/ þ rats compared with the vehicle-
treated group, and the creatinine clearance was 56% higher
(Table 2; Figure 1c and d). Thus, despite increased urine output
and lower body weight, the decline in renal function was
significantly attenuated in the phlorizin-treated rats.
Plasma blood urea nitrogen values increased to a greater
extent upon treatment of Cy/ þ rats with phlorizin compared
with vehicle (Table 2). However, blood urea nitrogen values
also increased upon treatment with phlorizin in þ / þ
control rats. This is consistent with an enhanced tubular
reabsorption of urea upon induction of osmotic diuresis.
As albuminuria is a marker of renal disease severity in the
Han:SPRD model of PKD, we determined the amount of
urinary albumin in Cy/ þ and þ / þ rats treated with
phlorizin or vehicle by enzyme-linked immunosorbent assay
(ELISA) and SDS–polyacrylamide gel electrophoresis.
Figure 2 shows that albumin excretion was higher in Cy/ þ
compared with wild-type þ / þ rats, as expected. The
excretion of urinary albumin was significantly reduced upon
treatment of Cy/ þ rats with phlorizin. After 5 weeks of
treatment, the albumin excretion amounted to 2.7± 0.7 mg/
day in vehicle-treated Cy/ þ rats vs. 1.0± 0.4 mg/day in
phlorizin-treated animals (63.1% less in the phlorizin-treated
group compared with the vehicle-treated group, Po 0.01).
Table 1 | Effect of phlorizin treatment on body weight, diuresis, and fluid and electrolyte parameters in Cy/ þ rats
Day 17 Day 35
Baseline CON PHLO CON PHLO
Number of animals (n) 17 7 10 7 10
Age (in weeks) 5 7.5 7.5 10 10
Total body weight (g) 94.5± 2.5 212.8± 8.7 186.7± 7.3* 304.7± 9.4 284.2± 5.5*
Diuresis (ml/day) 4.5± 0.4 14.3± 1.4 47.6± 3.8*** 23.6± 2.9 65.0± 2.2***
Posm (mosm/l) 300.5± 16.4 306.3± 5.5 306.7± 7.9 310.2± 4.1 314.2± 16.9
PNaþ (mmol/l) 143.7± 2.8 144.9± 3.6 144.4± 3.1 144.3± 3.7 144.7± 8.8
PCl  (mmol/l) 104.8± 2.3 102.6± 1.3 103.4± 2.5 104.7± 4.7 104.6± 6.8
Pglucose(mmol/l) 9.3± 0.8 11.3± 1.2 11.1± 1.6 12.9± 3.0 13.0± 3.8
Uosm (mosm/day) 8.3± 2.4 18.7± 4.0 47.0± 7.3*** 17.2± 2.3 49.1± 13.6***
Uglucose (mmol/day) o 0.1 0.1± 0.0 21.5± 2.9*** 0.1± 0.0 18.0± 4.6***
UNaþ (mmol/day) 0.6± 0.2 1.2± 0.2 1.7± 0.1** 1.1± 0.2 1.9± 0.8**
UCl  (mmol/day) 1.3± 0.4 2.7± o.6 3.1± 0.5 2.2± 0.4 3.4± 1.1***
Abbreviations: CON, vehicle (propylene glycol) treated; PHLO, phlorizin.
*Po 0.05, **Po 0.01, ***Po 0.001 when comparing CON and PHLO at each time point.
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Figure 1 | Diuresis, osmolar excretion, and renal function in
control ( þ / þ ) and cystic (Cy/ þ ) male Han:SPRD rats treated
with vehicle (propylene glycol; CON) or phlorizin (PHLO). (a)
Course of diuresis, (b) 24-h osmolar excretion, (c) plasma creatinine,
and (d) creatinine clearance from baseline to days 17 and 35 of
treatment. **Po 0.01, ***Po 0.001 when comparing Cy/ þ CON and
Cy/ þ PHLO at each time point. #Po 0.05 when comparing Cy/ þ and
þ / þ group.
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This suggests that the accompanying glomerular and
proximal tubular damage was strongly attenuated in
phlorizin-treated Cy/ þ .
Effect of phlorizin treatment on kidney weight and
morphology
After 5 weeks of treatment with phlorizin or vehicle, rats were
killed and the kidneys were excised and decapsulated for
weight determination and morphological analysis. The total
weight of both kidneys amounted to 6.96± 0.59 g in vehicle-
treated Cy/ þ (n¼7) vs. 5.66± 0.35 g in phlorizin-treated
Cy/ þ rats (n¼10), representing a difference of 18.7%
(Po 0.001). Figure 3a shows that the 2-kidneys/body weight
ratio was reduced by 12.6% in the phlorizin-treated rats
(Po 0.001). Likewise the cyst index (determined on periodic
acid–Schiff-stained sections) was reduced by 28.4% in
phlorizin-treated rats (Po 0.05). The cyst index data were
confirmed by further histomorphological analysis of the
kidneys, which demonstrated that phlorizin-treated Cy/ þ
rats had fewer and smaller cyst profiles as compared with
vehicle-treated rats (Figure 4).
Phlorizin inhibits proliferation of cyst epithelium
Immunostaining for Ki67 was used to examine whether
phlorizin treatment had an effect on cystic epithelial cell
Cy/+ CON Cy/+ PHLO +/+ CON +/+ PHLO
0
1
2
3
4a
b
↓  63.1%
**
Al
bu
m
in
ur
ia
 (m
g/
d)
Cy/+ CON
Albumin
Cy/+ PHLO M +/+ CON +/+ PHLO
65 kDa
Figure 2 | Albumin excretion in Cy/ þ and þ / þ rats after 5
weeks of treatment with vehicle (propylene glycol; CON) or
phlorizin (PHLO). (a) Urine albumin concentration (Cy/ þ CON:
n¼7; Cy/ þ PHLO: n ¼10; þ / þ CON: n¼5; þ / þ PHLO: n¼3).
**Po 0.01; (b) Urine sample SDS–polyacrylamide gel electrophoresis.
Each lane shows a urine sample of a single rat, each group shows
representative samples from three rats. Loading volumes were
corrected for diuresis and amounted to 15ml for vehicle-treated rats,
and 45ml for phlorizin-treated rats. Arrow shows the band for
albumin. M, marker.
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Figure 3 | Effect of phlorizin on kidney weight and cyst index.
Ratio of (a) 2-kidneys/body weight (2K/BW) and (b) cyst index in male
Cy/ þ rats treated daily for 5 weeks with vehicle (propylene glycol;
CON; n ¼7) or phlorizin (PHLO, n¼10). *Po 0.05, ***Po 0.001.
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Figure 4 | Effect of phlorizin on renal histology. Renal histology
(periodic acid–Schiff) in (a, c) vehicle-treated (propylene glycol; CON)
and (b, d) phlorizin-treated (PHLO) male Cy/ þ rats. Scale bar is
2000mm in a and b, and 200mm in c and d.
Table 2 | Effect of phlorizin on parameters of renal function in Cy/ þ and þ / þ rats
BUN (mg/dl) Creatinine (mg/dl) Creatinine clearance (ml/day)
Group Time point (day) CON PHLO CON PHLO CON PHLO
Cy/ þ Baseline 39.7± 5.6 41.0± 4.7 0.14± 0.03 0.15± 0.03 2.04± 0.50 1.67± 0.68
D17 53.8± 4.4www 65.0± 8.1*ww 0.18± 0.04 0.17± 0.03 3.40± 0.37 3.86± 0.93
D35 77.8± 14.8ww 76.6± 13.0ww 0.35± 0.08w 0.25± 0.05* 2.34± 0.81w 4.15± 0.14*
þ / þ Baseline 38.3± 3.9 35.2± 4.1 0.15± 0.02 0.17± 0.01 1.64± 0.39 1.99± 0.15
D17 38.2± 4.3 50.3± 12.4 0.18± 0.01 0.16± 0.02 3.50± 0.12 4.18± 0.37
D35 36.1± 2.3 53.1± 10.8* 0.22± 0.03 0.21± 0.03 4.56± 1.26 4.82± 1.01
Abbreviations: BUN, blood urea nitrogen; CON, vehicle (propylene glycol) treated; PHLO, phlorizin.
*Po 0.05 when comparing CON and PHLO at each time point. wPo 0.05; wwPo 0.01; wwwPo 0.001 when comparing Cy/ þ and þ / þ at each time point for the same
treatment.
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proliferation. Figure 5 demonstrates a marked increase in the
positivity of nuclei in the cystic and non-cystic epithelium of
Cy/ þ kidneys in comparison with wild-type þ / þ kidneys.
Quantification of the Ki67-positive nuclei revealed that the
number of Ki67-positive nuclei was 39.8% lower in cystic
epithelium and 23.8% lower in dilated tubules in phlorizin-
versus vehicle-treated Cy/ þ rats (Table 3). These data
suggest that phlorizin may directly affect cell proliferation.
Effect of phlorizin treatment on mitogen-activated protein
kinase and mTOR signaling pathway
We then studied the effect of phlorizin treatment on the
phosphorylation of two key kinases that are known to be
activated in PKD, namely extracellular signal-regulated kinase
(ERK; mitogen-activated protein kinase (MAPK) pathway)
and S6K (mTOR pathway). Figure 6 demonstrates that the
phosphorylation and the ratio of phosphorylated to total
ERK and S6K were markedly increased in Cy/ þ compared
with wild-type þ / þ rat kidneys. Of importance, phlorizin
treatment was associated with a significant decrease in the
phosphorylation of ERK, whereas the phosphorylation of
S6K was unchanged. These data suggest that phlorizin
differentially inhibits signaling cascades in the Cy/ þ kidneys.
50 μm 50 μm
50 μm 50 μm
20 μm 20 μm
Figure 5 | Representative areas of Ki67 immunohistochemical
staining in Cy/ þ rat kidneys. (a) Cy/ þ CON (cyst), (b) Cy/ þ
phlorizin (PHLO; cyst), (c) Cy/ þ CON (dilated tubule), (d) Cy/ þ PHLO
(dilated tubule), (e) þ / þ CON, and (f) þ / þ PHLO.
Table 3 | Effect of phlorizin treatment on Ki67 staining of
Cy/ þ rat kidneys
Treatment
CON
(n ¼4)
PHLO
(n ¼7)
Difference
(%) P-value
Ki67-positive cells in dilated tubules 2.8± 0.7 1.9± 0.3  23.8 0.037
Ki67-positive nuclei in cyst-lining
epithelium
5.8± 2.3 3.5± 1.5  39.8 0.029
Abbreviations: CON, vehicle (propylene glycol) treated; PHLO, phlorizin.
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Figure 6 | Effect of phlorizin on ERK and S6K phosphorylation.
(a) Western blot analysis and (b) densitometry for mammalian target
of rapamycin and mitogen-activated protein kinase pathway in þ / þ
and Cy/ þ kidney. Cy/ þ rats show enhanced phosphorylation of
extracellular signal-regulated kinase (ERK) and S6K compared with
wild-type þ / þ animals. In phlorizin-treated Cy/ þ rats, the
phosphorylation of ERK and the pERK/total ERK ratio is significantly
reduced, whereas the phosphorylation of S6Kand the pS6K/total S6K
ratio is unchanged. CON, propylene glycol treated; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; PHLO, phlorizin.
*Po 0.05, ***Po 0.001.
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Figure 7 | Western blot analysis for phosphorylated extracellular
signal-regulated kinase 1/2 (pERK; top) and total ERK (bottom) in
response to phlorizin treatment (0–1000lmol/l) in cultured Cy/ þ
tubular epithelial cell (TEC). TEC cultured from þ / þ kidneys
served as control. Bottom bar graph shows the densitometric pERK/
total ERK ratios.
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Effect of phlorizin on MAPK signaling pathway
To test whether phlorizin has a direct effect on MAPK
activation, we examined the effect of phlorizin in cultured
tubular epithelial cells (TECs) derived from Cy/ þ kidneys.
Figure 7 shows that ERK phosphorylation was constitutively
upregulated in TECs derived from Cy/ þ cells, contrasting
with the much weaker ERK phosphorylation, which is seen in
TECs that are derived from wild-type þ / þ rats. Upon
incubation of the cells with phlorizin (0–1000mmol/l), there
was a dose-dependent decrease of ERK phosphorylation. This
suggests that phlorizin via this direct effect on the MAPK
signaling pathway could directly alter TEC activation and
proliferation in PKD.
DISCUSSION
Treatment strategies for PKD with drugs that aim for renal-
specific targets may provide superior efficacy and fewer
adverse events, compared with therapeutic agents that have a
broader and less selective effect. The SGLT system may be one
of these renal-specific targets in PKD, and SGLT inhibitors
might have a potential benefit in PKD, either by directly
affecting cell proliferation or indirectly via their osmotic
diuresis effect. Drugs that specifically inhibit the kidney-
specific SGLT2 are currently being developed for glycemic
control in type 2 diabetes.7,8 Most of the SGLT2 inhibitors are
structurally derived from phlorizin, which is a powerful
inhibitor of both SGLT1 and SGLT2, and is known to
produce massive glycosuria and osmotic diuresis in the rat.6,9
Here, we show for the first time that chronic inhibition of
SGLT and induction of glycosuria with phlorizin slows renal
cystic disease progression in the Han:SPRD rat model of
PKD.10 A 5-week treatment course with phlorizin resulted in
the following: (1) improved renal function, as assessed by
plasma creatinine and creatinine clearance measurements;
(2) a reduction in urinary albumin excretion, which is a
marker of disease progression in this model; (3) a lower total
kidney weight and 2-kidneys/body weight ratio, correlating
morphologically with smaller cysts and a lower cyst index;
(4) decreased tubular and cystic epithelial cell proliferation,
as assessed by Ki67 staining; (5) inhibition of the activated
MAPK pathway, as assessed by a lower p-ERK1/2 to total
ERK ratio, both in vivo and in vitro. Thus, phlorizin-
mediated induction of glycosuria and the subsequent
occurrence of osmotic diuresis (glycuresis) were associated
with reduced cystic disease progression.
The putative mechanisms by which phlorizin inhibits
cystic renal disease progression may be manifold and must be
discussed at several levels. First of all, phlorizin may directly
inhibit cyst epithelial cell proliferation. This is suggested by a
markedly reduced number of proliferating cyst epithelial cells
in phlorizin-treated Cy/ þ rats. In addition, our in vitro
experiments with cultured Cy/ þ TECs show that phlorizin
has a direct effect on the MAPK pathway, which manifests as
an inhibition of ERK1/2 phosphorylation. Second, by
inducing osmotic diuresis phlorizin might change the
transepithelial transport of fluid and electrolytes in a way
that inhibits cyst growth. From the present studies, however,
it is not possible to provide a mechanism how osmotic
diuresis could reverse fluid secretion into the cysts. Third, a
change in the hormonal environment (in particular the
inhibition of insulin and insulin-like growth factor-1
production) is likely to be caused by the loss of glucose in
the urine and/or by a direct effect of phlorizin on insulin
secretion. As insulin and insulin-like growth factor-1 are
known to be implicated in cyst epithelial cell proliferation,
the reduced cyst development that is seen with phlorizin
treatment could be partially explained by these hormonal
changes.11,12
Treatment with phlorizin did not result in a stop or
reversal of disease progression. The treatment was well
tolerated by the rats and did not result in notable side effects,
except for a threefold increase in the urine output, which was
compensated by an appropriate increase in fluid intake. As
the activated MAPK13 and the mTOR pathway (reviewed in
Torres et al.14) critically contribute to the pathogenesis of
PKD, one could postulate that SGLT inhibitors might be ideal
drugs to combine with drugs that affect different signaling
pathways, such as the mTOR pathway that was not affected
by phlorizin in this study. We and others have previously
shown that treatment with sirolimus15,16 or everolimus17
significantly inhibited cyst growth and disease progression in
Han:SPRD rats. The effect of mTOR inhibitors on cyst
volume growth is only partial, perhaps because of the known
compensatory upregulation of the MAPK pathway.18
Combining SGLT inhibitors with mTOR inhibitors might
therefore be a therapeutic strategy worthwhile pursuing in
PKD.
It might be of interest to oppose the effect of phlorizin
(a glycuretic drug) and the effect of the vasopressin type 2
receptor antagonist tolvaptan (an aquaretic drug), the latter
of which is in phase 3 clinical development for the treatment
of ADPKD.19,20 Both drugs target highly selective renal
tubular transport systems and produce a significant and
sustained increase in urine output. Similar to phlorizin,
tolvaptan is also known to inhibit the ERK pathway but not
the mTOR pathway.21,22 At this point, it is not known
whether the vasopressin–cAMP axis is altered with phlorizin.
In view of the primary increase in the osmotic clearance,
treatment with phlorizin could lead to increased endogenous
AVP levels—an effect similar to that observed with long-term
vasopressin type 2 receptor antagonism—23 and this could
promote distal tubular cyst growth, an effect that might not
be seen in Han:SPRD as the cysts are almost exclusively of
proximal tubular origin, which are not supposed to be
responsive to vasopressin. Of note, increasing fluid intake
and urine output experimentally by providing rats with 5%
glucose in the drinking water also revealed a beneficial effect
on cyst growth in a distal PKD model (PCK rat) but not in
the proximal model (Han:SPRD rat).24 Thus, glycuretic and
aquaretic drugs display similar and dissimilar effects on cyst
volume progression and should be developed further as a
future treatment for ADPKD.
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By now there is no evidence that chronic SGLT inhibition
may potentially be deleterious for the kidney. Results from
Sglt2 /  knockout mice25 and more recently from Sglt1 / 
knockout mice26 have revealed that there is no alteration in
renal function and morphology. As in phlorizin-treated rats,
Sglt2 /  mice display glycosuria, polyuria, and increased
food and fluid intake without differences in plasma glucose
concentrations and glomerular filtration rate compared with
wild-type mice. SGLT2 deficiency is also not associated with
volume depletion, as shown by similar body weight, BP, and
hematocrit. Likewise, human familial renal glycosuria that
results from mutations in the SGLT2 gene is considered to be
a benign condition.27 As far as we know, the renal safety of
the SGLT2 inhibitor dapagliflozin (in clinical development
for type 2 diabetes) is excellent, except for a slightly higher
incidence of genitourinary infections.28
In summary, we have shown that induction of glycosuria
and osmotic diuresis (glycuresis) by inhibition of the renal
SGLT with phlorizin resulted in a significant retardation of
the cystic disease progression in the Han:SPRD rat model
of PKD. Further studies are in progress to assess the effect of
glycosuria induction in additional models of PKD, including
the ARPKD model in PCK rats. Whether this experimental
strategy can be translated to human ADPKD remains to be
determined.
MATERIALS AND METHODS
Animals
The Han:SPRD rat colony was established in our animal facility
from a litter, which was obtained from the Rat Resource and
Research Center (Columbia, MO). Heterozygous cystic (Cy/ þ ) and
wild-type normal ( þ / þ ) rats were used in this study. Only male
rats were used as cysts develop more rapidly in male compared with
female rats. The regulatory commission for animal studies, a local
government agency, approved the study protocol. Rats had free
access to tap water and standard rat diet.
Study design
Treatment was started in 5-week-old male heterozygous Cy/ þ or
wild-type þ / þ control Han:SPRD rats. Groups of 7–10 rats were
used. Phlorizin (Sigma-Aldrich, Buchs, Switzerland) was dissolved
in a solution of 60% propylene glycol in phosphate-buffered saline
and was injected subcutaneously at a dose of 400 mg/kg/day for
5 weeks. Control rats were injected with the same volume of 60%
propylene glycol in phosphate-buffered saline. The dose of the
phlorizin or the vehicle was adjusted daily according to the body
weight of the rats. Blood and urine were collected at baseline (before
treatment), at day 17 and 35 of treatment in all animals. All samples
were stored at  201C before measurement. Rats were killed after
5 weeks of treatment, and kidneys were harvested for further analysis.
The Synchron LX System, UniCel DxC 600/800 System, and
Synchron System AQUA CAL 1 and 2 (Beckman, Brea, CA) were
used for the quantitative determination of glucose, sodium,
chloride, creatinine, and blood urea nitrogen concentrations in rat
plasma and urine. Plasma and urine osmolalities were measured by
using an Advanced freezing-point osmometer.
The GenWay (San Diego, CA) rat albumin ELISA kit was used
for urine albumin concentration measurements. The urine samples
were diluted 500 times in the diluent solution. One-hundred
microliter aliquots of albumin standard or urine sample were added
into each well of precoated plates. Plates were incubated for 30 min
at room temperature and were washed four times thereafter. Plates
were then incubated with horseradish peroxidase–conjugated anti-
albumin solution for 30 min at room temperature in the dark, and
were washed again four times. Then 100ml of 3,30,5,50-tetramethyl-
benzidine substrate solution was added into each well, and plates
were incubated in the dark for 10 min at room temperature. Then
100ml stop solution was added, mixed well, and the absorbance at
450 nm was determined using a Tecan ELISA reader (Ma¨nnedorf,
Zu¨rich, Switzerland).
Tissue sectioning, periodic acid–Schiff staining, and cyst
index determination
For the histological examination, one of the kidneys from each
animal was sliced perpendicularly to the long axis at B 2-mm
intervals. Slices from the midportion of the kidneys were fixed in
10% buffered formalin overnight. On the next day tissues were
embedded in paraffin. Three-micrometer sections were stained with
periodic acid–Schiff following routine protocols. The stained
sections were subjected to cyst index analysis, using the HistoQuest
image analysis software (TissueGnostics, Vienna, Austria) to count
the whole cortex region (total area, TA) and the cyst area (cyst area,
CA) in the renal cortex. The cyst index was calculated as CA/
TA100.
Immunohistochemistry
Immunohistochemistry for Ki67 was performed on 3-mm tissue
sections. In brief, the tissue sections were deparaffinized and
rehydrated. The antigen retrieval was performed in an autoclave
oven. As primary antibody we used a mouse anti-Ki67 antibody (BD
Pharmingen, San Jose, CA). After applying the primary antibody for
1 h the sections were washed, and then incubated with the
biotinylated secondary antibody (Vector, Los Angeles, CA) for
30 min. This was followed by the application of the ABC reagent
(Vector), using 3,30-diaminobenzidine with metal enhancement as
the detection reagent.
For each section we randomly chose 10 cysts, counted the
number of Ki67-positive nuclei, and then averaged the number of
Ki67-positive nuclei per cyst. We also chose 10 areas with dilated
tubules and counted the number of Ki67-positive dilated tubules
and the number of positive Ki67 nuclei per tubule, and then
averaged the Ki67-positive nuclei in each positive dilated tubule.
Western blot analysis
Kidneys were homogenized with ice-cold lysis buffer containing
40 mmol/l Hepes, 120 mmol/l NaCl, 1 mmol/l ethylenediaminete-
traacetic acid, 10 mmol/l potassium pyrophosphate, 10 mmol/l
glycerol phosphate, 50 mmol/l NaF, 0.5 mmol/l NaVO3, 1% Triton-
X 100, and protease inhibitor mixture (pH 7.6). Tissue lysates were
cleared by centrifugation. Equal amounts of lysates were resolved by
SDS–polyacrylamide gel electrophoresis, transferred to nitrocellulose
membranes, and probed with antibodies against ERK1/2Thr202/Tyr204,
ERK1/2, p70 S6K Thr421/Ser424, p70 S6K (all from Cell Signaling
Technology, Danvers, MA), and glyceraldehyde-3-phosphate dehy-
drogenase. Sheep anti-mouse IgG-HRP and donkey anti-rabbit IgG-
HRP were used as secondary antibodies. Quantification of
phosphorylated ERK1/2 and p70 S6K expression was normalized
for total ERK1/2 and p70 S6K, respectively, using a densitometer,
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and the data are reported as ratio of phlorizin- versus vehicle-treated
Cy/ þ and þ / þ rats.
Primary cultures of TECs from Cy/ þ rats
Primary cultures of TECs from 8-week-old þ / þ and Cy/ þ
kidneys were prepared by mincing the kidneys and digesting the
tissues with 1 mg/ml collagenase with gentle agitation for 1 h at
371C. The suspension was allowed to sediment for 1 min. Cells were
collected by harvesting the supernatant twice, and were then washed
three times with 10% fetal bovine serum (FBS)/Hanks balanced salt
solution. Isolated cells were resuspended in K1 medium (1:1 mixture
of Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium
supplemented with 5% FBS, 10 mmol/l HEPES, 42 mmol/l sodium
bicarbonate, 50 ng/ml insulin, 50 nmol/l hydrocortisone, 50 ng/ml
transferrin, 5 pmol/l triiodothyronine, 20 ng/ml rat EGF, 100 IU/ml
penicillin, and 100mg/ml streptomycin). Cells were then seeded in
collagen type 1–precoated culture dishes and grown to confluence.
The medium was then changed to a K1 medium with 0.5% FBS for
24h, and the cells were then incubated with phlorizin (0–1000mmol/l)
for 24 h. Lysates were then prepared and resolved by SDS–
polyacrylamide gel electrophoresis and probed by western blot
analysis with antibodies against ERK1/2Thr202/Tyr204 and total ERK1/2
as described above.
Statistical analysis
Data are presented as means± s.d. Data were tested for statistically
significant differences between treatment groups by using the
unpaired two-tailed t-test, and by using the GraphPad Prism
version 5.0 software (GraphPad, San Diego, CA). Po 0.05 was
considered to indicate statistically significant differences.
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Abst ract
Background/ Aims: DapagliÁozin (DAPA) is a selective inhibitor of the sodium-glucose 
cotransporter 2 (SGLT2) which induces glucosuria and osmotic diuresis. The therapeutic 
effect of DAPA in progressing stages of polycystic kidney disease (PKD) has not been studied. 
Methods: We examined the effect of DAPA in the Han: SPRD rat model of PKD. DAPA (10 mg/
kg/day) or vehicle (VEH) was administered orally via gavage to 5 week old male Han: SPRD 
(Cy/+) or control (+/+) rats (n = 8-9 per group) for 5 weeks. Blood and urine were collected at 
baseline and after 2.5 and 5 weeks of treatment to assess renal function and albuminuria. At 
the end of the treatment, rats were sacriÀced and kidneys were excised for histological analysis. 
Results: After 5 weeks of treatment, DAPA-treated Cy/+ and +/+ rats exhibited signiÀcantly 
higher glucosuria, water intake and urine output than VEH-treated rats. DAPA-treated Cy/+ 
rats also exhibited signiÀcantly higher clearances for creatinine and BUN and less albuminuria 
than VEH-treated Cy/+ rats. DAPA treatment for 5 weeks resulted in a signiÀcant increase of 
the kidney weight in Cy/+ rats but no change in cyst growth. The degree of tubular epithelial 
cell proliferation, macrophage inÀltration and interstitial Àbrosis was also similar in DAPA- 
and VEH-treated Cy/+ rats. Conclusion: The induction of glucosuria with the SGLT2-speciÀc 
inhibitor DAPA was associated with improved renal function and decreased albuminuria, but 
had no effect on cyst growth in Cy/+ rats. Overall the beneÀcial effects of DAPA in this PKD 
model were weaker than the previously described effects of the combined SGLT1/2 inhibitor 
phlorizin.
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Int roduct ion
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common form 
of cystic renal diseases, affecting all ethnic groups worldwide, with an incidence of 1:400-
1:1.000 [1, 2]. The disease is caused by a mutation in the PKD1 or the PKD2 genes that 
encode for the proteins polycystin-1 (PC1) and polycystin-2 (PC2) [3]. Altered function and/
or a decrease of PC1 or PC2 levels below a certain threshold lead to slow and continuous 
development of luid-illed cysts [4], resulting in bilateral renal enlargement and end-stage 
renal disease (ESRD) in approximately half of the patients [5].
Since ADPKD is relentlessly progressing, effective and speciic long-term therapies are 
needed to halt disease progression. Several drugs are being tested in clinical trials, and some 
are emerging to be effective in selected patients [6]. Tolvaptan, in particular, is an aquaretic 
drug which inhibits the vasopressin V2 receptor in the distal nephron and causes a massive 
increase in diuresis, thereby suppressing the renal cAMP production and its stimulatory 
effect on cyst growth [7].
The sodium-glucose cotransporters (SGLTs) are a family of membrane proteins which 
are involved in the transepithelial transport of glucose in the kidneys and the gut. Within 
the kidney, SGLT1 is located in the S3 segment of the proximal renal tubule, whereas 
SGLT2 is found in the S1 segment [8]. SGLT1 is a low-capacity, high-afinity sodium-glucose 
cotransporter, responsible for 10% of glucose reabsorption, whereas SGLT2 is a high-
capacity, low-afinity transporter which mediates 90% of glucose reabsorption [9]. The 
pharmacological inhibition of SGLTs leads to glucosuria which is accompanied by a constant 
increase in diuresis. In analogy to the tolvaptan-induced increase in diuresis which has 
beneicial effects in PKD we speculated that the increase in diuresis which is caused by 
SGLT inhibitors could also decrease cyst growth in PKD. In a previous study, we have already 
demonstrated that phlorizin, a dual SGLT1/ 2 inhibitor, reduced cyst growth and slowed the 
decline of renal function in the Han: SPRD rat model of PKD [10]. The inhibition of SGLTs 
was associated with a decrease in ERK1/ 2 phosphorylation and tubular epithelial cell (TEC) 
proliferation in the polycystic kidneys.
Dapaglilozin (DAPA) is a selective SGLT2 inhibitor that is clinically used to control 
glycemia in patients with type 2 diabetes mellitus [11]. DAPA is well absorbed when given by 
the oral route, whereas phlorizin needs to be applied parenterally since it is only minimally 
absorbed when applied orally [12]. By causing glucosuria, DAPA effectively corrects 
hyperglycemia and reduces hemoglobin A1c in patients with type 2 diabetes mellitus [13]. 
We hypothesized that - similar to phlorizin - DAPA might also have a therapeutic effect in 
PKD. The purpose of the present study was therefore to assess whether DAPA can reduce 
cyst growth and improve renal function in heterozygous (Cy/ +) Han: SPRD rats.
Materials and Methods
Animals
The Han: SPRD rat colony was established in our animal facility from a litter which was obtained 
from the Rat Resource and Research Center (Columbia, MO, USA). Heterozygous cystic (Cy/ +) and wild-type 
normal (+/ +) rats were used in this study. Only male rats were used since cysts develop more rapidly in male 
than in female rats. The regulatory commission for animal studies, a local government agency, approved the 
study protocol. Rats had free access to tap water and standard rat diet.
Study design
Treatment was started in 5-week old male Cy/ + and wild-type +/ + control Han:SPRD rats. Groups 
of 8-9 rats were used. DAPA was dissolved in 45% propylene glycol + 45% H2O + 10% ethanol and was 
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given daily by gavage at a dose of 10 mg/ kg for 5 weeks. Control rats were treated with vehicle (45% 
propylene glycol + 45% H2O + 10% ethanol) alone. Blood and 24 h urines were collected from each animal 
at baseline (before treatment), and after 2.5 and 5 weeks of treatment. Blood was taken from the sublingual 
vein, centrifuged and the plasma collected. Urines were collected in metabolic cages over a 24 h period. All 
samples were stored at -80°C prior to further examination. In the plasma glucose, creatinine, blood urea 
nitrogen (BUN), sodium and chloride concentrations were determined, and the urine was tested for glucose, 
creatinine and BUN concentrations, using standard clinical chemistry methods. After 5 weeks of treatment, 
rats were euthanatized with isolurane (Attane, Piramal Healthcare Limited, India) and both kidneys were 
excised, decapsulated, weighed and ixed in 10% buffered formalin for 2 days for histological analysis.
Urine albumin determination
A rat albumin ELISA kit was used for the measurement of urine albumin concentration (GenWay, San 
Diego, California). The urine samples were diluted 500 times in the diluent solution. Albumin standard 
or urine sample were added to the pre-coated plates (100 µl/ well). Plates were incubated for 30 min at 
room temperature and washed 4 times thereafter with phosphate-buffered saline (PBS). Plates were then 
incubated with horseradish peroxidase-conjugated anti-albumin solution for 30 min at room temperature 
in the dark, and washed again 4 times. Then 100 µl 3,3′,5,5′-tetramethylbenzidine substrate solution was 
added into each well, and plates were incubated in the dark for 10 min at room temperature. Then 100 µl 
stop solution was added, mixed well, and the absorbance at 450 nm was determined using a Tecan ELISA 
reader (Tecan Group Ltd, Männedorf, Switzerland).
Histology and immunohistology
One kidney was longitudinally cut in half and approximately 2 mm thick slices were embedded in 
parafin wax. Consecutive sections (3-5 µm) were prepared and stained with hematoxylin-eosin, the PAS 
reaction and Gomori’s Blue Trichrome using the Artisan Link stainer (Dako, Baar, Switzerland).
Immunohistology was used to stain for Ki67-positive (proliferating) TEC and CD68-positive iniltrating 
macrophages, using a Dako Autostainer (Dako) and the streptavidin horseradish peroxidase (HRP) method. 
After deparafinization and rehydration, sections were incubated in citrate buffer (pH 6.0) for 20 min at 95°C 
in a pressure cooker. After washing in TBS-Tween, slides were incubated for 60 min at room temperature 
with the primary antibodies (mouse anti-rat Ki67 [clone MIB-5, Dako], mouse anti-rat CD68 [clone ED1, 
AbD Serotec, Kidlington, UK]) at a dilution of 1:10 and 1:500 in dilution buffer (Dako), respectively. This 
was followed by incubation with the secondary antibody for 15 min, the peroxidase blocking solution for 10 
min, and the streptavidin HRP for 15 min. After washing, the reaction was visualized by incubation with 3, 
3’-diaminobenzidine for 10 min, followed by counterstaining with hemalaun (Merck, Darmstadt, Germany).
Histomorphometry
PAS-stained sections were subjected to cyst index analysis, using the HistoQuant image analysis 
software (3DHISTECH Kft., Budapest, Hungary) to assess the cortical cystic area (CCA) within the entire 
cortex (total area, TA). The cyst index was calculated as CCA/ TA*100. We counted the total number of cysts 
detected in 2 full longitudinal sections of each kidney and then averaged the total number of cysts. We 
calculated the area of each cyst, then counted and arranged them by size. For each section stained for the 
expression of Ki67, the total number of Ki67-positive nuclei was counted, from which an average number of 
Ki67-positive nuclei per mm2 of tissue was calculated. For each section stained for the expression of CD68, 
the total number of CD68-positive cells was counted, from which an average number of CD68-positive nuclei 
per mm2 of tissue was calculated. The extent of ibrosis was determined on Gomori’s Blue Trichrome stained 
sections by measuring the collagen stained area in mm2 and dividing it by the total area of tissue in mm2.
Statistical analysis
Data are presented as means ± SD. Statistical differences between treatment groups were assessed by 
the unpaired two-tailed t-test using Graph Pad Prism version 5.0 (Graph Pad, San Diego, CA, USA). P < 0.05 
was considered to be statistically signiicant.
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Results
DAPA induced glucosuria and increased diuresis
Treatment with DAPA effectively induced glucosuria and increased the urine output 
in Cy/ +rats (Table 1). Alongside the increased diuresis, an increase in water intake was 
observed with DAPA treatment. The body weight gain was not altered with DAPA in Cy/ +. 
A mild increase in urine Na+ and Cl- was seen upon treatment with DAPA in Cy/ + (Table 1).
DAPA preserved the decline of the creatinine and BUN clearances in Cy/ + rats
With increasing age, the clearances for creatinine and BUN increased in VEH- and DAPA-
treated +/ + rats to a similar level (Table 2). In VEH-treated Cy/ + rats, creatinine and BUN 
clearances decreased during the 5-week treatment phase, in parallel with the development 
of renal cysts. In contrast, DAPA treatment in Cy/ + rats led to preservation of the creatinine 
and BUN clearances at 2.5 and 5 weeks of treatment (Table 3).
DAPA reduced albuminuria in Cy/ + rats
Albuminuria increased signiicantly in VEH-treated Cy/ + rats between baseline and 
week 5. However, DAPA-treated Cy/ + rats showed a signiicantly lower urine albumin 
excretion than the VEH-treated rats after 5 weeks of treatment (Table 1).
Table 1. Effects of DAPA on body weight, diuresis, and luid and electrolyte parameters in Cy/ + rats. Results 
are expressed as mean ± SD. Comparisons are made between DAPA and VEH groups at the same time point. 
Abbreviations: VEH, vehicle; DAPA, dapaglilozin; P, plasma; U, urine. *P < 0.05, ** P < 0.01, ***P < 0.001 
when comparing DAPA vs. VEH at each time point
Table 2. Effect of DAPA on parameters of renal function in +/ + rats. Results are expressed as mean ± SD. 
Comparisons are made between DAPA and VEH groups at the same time point. Abbreviations: BUN, blood 
urea nitrogen; VEH, vehicle; DAPA, dapaglilozin; P, plasma; U, urine. *P < 0.05, ***P < 0.001 when comparing 
DAPA vs. VEH at each time point
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DAPA increased kidney weight without effect on cyst growth
In +/ + and Cy/ + rats, treatment with DAPA for 5 weeks led to a signiicant increase 
in the kidney weight and the 2-kidneys/ body weight ratio (2KW/ BW) compared to VEH-
treated rats (Table 4). The histological examination of the kidneys revealed a slightly higher 
amount of non-cystic parenchyma but a similar cyst burden in DAPA-treated Cy/ + rats (Fig. 
1). Histomorphometric quantiication of the cyst burden revealed a similar cyst index in 
DAPA- and VEH-treated Cy/ + rats (20.3 ± 1.4 vs 21.9 ± 1.2%, P = 0.55) (Fig. 2A), a similar 
total number of cysts (1056 ± 225 vs. 994 ± 229, P = 0.67; Fig. 2B) and a similar size proile 
of the cysts (Fig. 2C). Altogether these data suggests that there was a higher amount of non-
cystic tissue in DAPA-treated Cy/ + rats.
Table 3. Effect of DAPA on parameters of renal function in Cy/ + rats. Results are expressed as mean ± SD. 
Comparisons are made between DAPA and VEH groups at the same time point. Abbreviations: BUN, blood 
urea nitrogen; VEH, vehicle; DAPA, dapaglilozin; P, plasma; U, urine. ** P < 0.01, *** P < 0.001 when compar-
ing DAPA vs. VEH at each time point
Table 4. Effect of DAPA on kidney weight in 10-week old +/ + and Cy/ + rats after 5 weeks of treatment. 
Results are expressed as mean ± SD. Comparisons are made between DAPA and VEH groups at the same 
time point. Abbreviations: VEH, vehicle; DAPA, dapaglilozin; 2KW, two-kidneys weight; BW, body weight. 
** P < 0.01, ***P < 0.001 when comparing DAPA vs. VEH at each time point
Fig. 1. PAS 
staining of kid-
ney sections. 
Sections are 
from 10 week 
old Cy/ + and 
+/ + rats treat-
ed with DAPA 
or VEH for 5 
weeks; scale 
bar is 2000 µm 
in upper images 
and 100 µm in 
lower images.
 
 
 
  
 
   
   
   
 
  
 
 
39
 Kidney Blood Press Res 2015;40:638-647
DOI: 10.1159/000368540
Published online: December 19, 2015
©  2015 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 643
Rodriguez et al.: DapagliÁozin and Polycystic Kidney
DAPA had no effect on renal tubular 
epithelial cell proliferation
The immunohistological staining for 
Ki67-positive tubular epithelial cells (TEC) 
showed that the number of Ki67-positive 
TECs was higher in Cy/ + than +/ + rats, 
suggesting enhanced TEC proliferation 
in Cy/ + rats (Fig. 3). The difference in the 
number of Ki67-positive TECs between 
DAPA- and VEH-treated +/ + rats was not 
signiicant (139 ± 87 vs. 163 ± 63 cells/ mm2, 
P = 0.67). DAPA-treated Cy/ + rats exhibited 
less proliferating TECs than VEH-treated 
animals (237 ± 109 vs. 327±60 Ki67-positive 
cells/ mm2), but the difference was also not 
signiicant (P=0.28) (Fig. 4A).
DAPA had no effect on renal macrophages 
iniltration
The degree of iniltration with macro-
phages was assessed by staining kidney sec-
tions for CD68. The number of CD68-positive 
cells was signiicantly higher in Cy/ + com-
pared to +/ + rats (20 ± 8 vs. 11 ± 6 CD68-pos-
Fig. 2. Histomorphometric analysis of cyst growth. 
PAS-stained kidney sections of 10 week old Cy/ + 
rats treated with DAPA or VEH for 5 weeks. (A) Cyst 
index (%). (B) Number of cysts (n). (C) Cyst classii-
cation by size, grey lines represent ranges for ± 1 SD.
itive cells/ mm2, P = 0.03). However, there was no difference between DAPA- and VEH-treated 
Cy/ + rats (19 ± 8 vs. 20 ± 8 ED-1-positive cells/ mm2, P = 0.85) (Fig. 4B).
DAPA had no effect on interstitial ibrosis
Using Gomori’s Blue Trichrome staining we quantiied the degree of renal interstitial 
ibrosis in Cy/ + and +/ + rats. The renal collagen index was slightly higher in Cy/ + vs. +/ + 
rat kidneys (5.3 ± 2.0 vs. 4.0 ± 0.8%, P = 0.12). DAPA treatment did not signiicantly change 
the collagen index in +/ + (2.9 ± 1.7 vs. 4.0 ± 0.8%, P = 0.11) and Cy/ + rats (4.5 ± 1.8 vs. 5.3 ± 
2.0%, P = 0.46) (Fig. 4C).
Discussion
Increasing water intake and diuresis was shown to have beneicial effects on the cystic 
disease progression in different rodent models of PKD [14-17]. The increased water intake 
suppresses vasopressin and reduces the translocation of aquaporin 2 from intracellular 
vesicles to the luminal membrane of the collecting duct, leading to increased diuresis [18]. 
Furthermore, in the case of PKD, inhibiting vasopressin with tolvaptan at the level of the 
V2 receptor in the collecting duct also increases diuresis and reduces intrarenal cAMP, 
thereby inhibiting cyst epithelial cell proliferation via MAP kinase [19]. The pharmacological 
inhibition of SGLTs leads to glucosuria which is also accompanied by a signiicant increase in 
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diuresis. In analogy to the tolvaptan-induced 
increase in diuresis which has beneicial 
effects in PKD we speculated that the 
increase in diuresis which is caused by SGLT 
inhibitors could also decrease cyst growth in 
PKD. Thus, by inducing osmotic diuresis and 
increasing urinary low to the collecting duct 
with the SGLT1/ 2 inhibitor phlorizin, we 
recently have shown that cyst growth, renal 
function and albuminuria improved in the 
Han:SPRD rat model of PKD [10].
In the present study, we examined the 
effect of DAPA, a selective SGLT2 inhibitor, 
on the cystic disease process in Han: SPRD 
rats. DAPA effectively induced glucosuria and 
osmotic diuresis but was less potent than 
the previously tested phlorizin. While DAPA 
improved the decline of renal function and 
improved albuminuria it did not decrease 
cyst growth, macrophage iniltration and 
interstitial ibrosis in Han: SPRD rats. All 
in all, the beneicial effects of the SGLT2-
selective inhibitor DAPA appeared to be 
Fig. 3. Histological analysis for Ki67, CD68 and interstitial ibrosis. Kidney sections were analyzed for TEC 
proliferation (immunostaining for Ki67), macrophage iniltration (immunostaining for CD68) and intersti-
tial ibrosis (Gomori’s Blue Trichrome). Arrowheads mark Ki67- or CD68-positive cells. Scale bar is 50 µm 
for Ki67 and CD68 stainings, and 100 µm in Gomori’s Blue Trichrome staining.
Fig. 4. Histomorphometric analysis for Ki67, CD68 
and interstitial ibrosis. (A) Ki67 quantiication 
(Ki67-positive cells/ mm2). (B) CD68 quantiication 
(CD68-positive cells/ mm2). (C) Fibrosis quantiica-
tion (collagen index in %).
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limited in Cy/ + rats, and are in contrast to the more important effects of the dual SGLT1/ 2 
inhibitor phlorizin.
Of interest, DAPA led an unexpected kidney enlargement which was not due to an 
increase in the cyst growth. An increase of kidney weight has also been noticed in Sglt2 
-/ - knockout mice [20]. Although we do not know the mechanisms behind this increase in 
kidney weight our histological analysis suggests that it is most likely caused by widening 
of the tubular lumen due to the increased diuresis. In addition there may also be a certain 
degree of tubular hypertrophy which could be related to an increase of the SGLT1-mediated 
glucose reabsorption in the S2 and S3 segment of the proximal tubules [21]. In a different 
setting, namely in SGLT1-transfected cardiomyocytes a hypertrophic response has also been 
noticed, suggesting that SGLT1-mediated enhanced glucose uptake may indeed affect cell 
size [22].
DAPA was developed as a selective SGLT2 inhibitor [23-25] and is in clinical use for the 
control of glycemia in patients with type 2 diabetes [26, 27]. Since DAPA is also known to 
increase diuresis [25-28], and given its oral availability and its favorable safety proile [29, 
30], we felt that it might be a potentially useful drug to retard disease progression in patients 
with ADPKD. With DAPA’s effect of increasing osmolality along the nephron we speculated 
that DAPA might also rebalance the transport of luid across the cyst epithelium, thereby 
preventing cyst expansion. As mentioned, DAPA was a less effective glucosuric agent than 
phlorizin and it did not inhibit cyst growth in the Han:SPRD rat model of PKD in the present 
study, presumably because much of the glucose is reabsorbed by the uninhibited SGLT1 in 
the proximal tubule [21].
To be effective in PKD, it would be desirable to develop a less selective SGLT inhibitor, 
displaying strong inhibition of SGLT2 and partial inhibition of SGLT1. This would decrease 
the SGLT1-mediated glucose reabsorption and enhance the urinary glucose excretion. Ideally 
such a drug should be orally available, and should not block SGLT1 in the gut completely 
which might cause glucose-galactose malabsorption and diarrhea [31]. The development 
of dual SGLT1/ 2 inhibitors would of course also be predicted to have stronger effects on 
glycemic control in patients with type 2 diabetes [32].
We recently tested DAPA in PCK rats, an orthologous model of autosomal recessive PKD 
(ARPKD) [33]. Whereas Han:SPRD rats develop cysts of proximal tubular origin in the cortex, 
PCK rats develop cysts of distal tubular origin in the medulla. Quite unexpectedly, we found 
that DAPA led to an increase of the cyst growth in PCK rats. Furthermore the DAPA-treated 
PCK rats displayed hyperiltration and albuminuria, eventually accelerating the decline 
in renal function. Although the renal function was improved with DAPA in Han:SPRD rats 
we did not ind evidence for hyperiltration, particularly since albuminuria was improved. 
Altogether the data suggest that DAPA has PKD model-speciic effects, and that the effect in 
human ADPKD could be unpredictable.
Conclusion
The SGLT2-selective inhibitor DAPA improved the decline of renal function and the extent 
of albuminuria in Han:SPRD rats with PKD, but it did not have a signiicant effect on cyst 
growth and secondary renal parenchymal alterations such as macrophage iniltration and 
ibrosis. Dual SGLT1/ 2 inhibitors with a stronger glucosuric effect are under development 
and should be considered for future testing in PKD.
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Abstract
The sodium-glucose-cotransporter-2 (SGLT2) inhibitor dapagliflozin (DAPA) induces gluco-
suria and osmotic diuresis via inhibition of renal glucose reabsorption. Since increased di-
uresis retards the progression of polycystic kidney disease (PKD), we investigated the
effect of DAPA in the PCK rat model of PKD. DAPA (10 mg/kg/d) or vehicle was adminis-
tered by gavage to 6 week old male PCK rats (n=9 per group). Renal function, albuminuria,
kidney weight and cyst volume were assessed after 6 weeks of treatment. Treatment with
DAPA markedly increased glucose excretion (23.6 ± 4.3 vs 0.3 ± 0.1 mmol/d) and urine out-
put (57.3 ± 6.8 vs 19.3 ± 0.8 ml/d). DAPA-treated PCK rats had higher clearances for creati-
nine (3.1 ± 0.1 vs 2.6 ± 0.2 ml/min) and BUN (1.7 ± 0.1 vs 1.2 ± 0.1 ml/min) after 3 weeks,
and developed a 4-fold increase in albuminuria. Ultrasound imaging and histological analy-
sis revealed a higher cyst volume and a 23% higher total kidney weight after 6 weeks of
DAPA treatment. At week 6 the renal cAMP content was similar between DAPA and vehicle,
and staining for Ki67 did not reveal an increase in cell proliferation. In conclusion, the inhibi-
tion of glucose reabsorption with the SGLT2-specific inhibitor DAPA caused osmotic diure-
sis, hyperfiltration, albuminuria and an increase in cyst volume in PCK rats. The
mechanisms which link glucosuria to hyperfiltration, albuminuria and enhanced cyst volume
in PCK rats remain to be elucidated.
Introduction
Polycystic kidney diseases (PKD) are the most frequent entities among the genetically deter-
mined renal syndromes [1]. The autosomal dominant form of PKD (ADPKD) is twenty times
more frequent than the autosomal recessive form (ARPKD) [2]. Approximately 5–8% of all pa-
tients with end-stage renal disease (ESRD) suffer from ADPKD [3]. Although progress has re-
cently been made in the development of treatments which retard the cystic growth, no therapy
was shown to be effective in delaying the occurrence of ESRD [4].
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It has been shown that renal cAMP is a major driver of cyst growth in PKD [5]. The exces-
sive cAMP production is a consequence of the genetic defect which underlies PKD [6]. Due to
an early loss of the urine concentrating capability the production of vasopressin is upregulated
in PKD, stimulating the production of cAMP directly through its V2 receptor in the distal renal
epithelium [7]. Therapeutic strategies which decrease the vasopressin-driven cAMP produc-
tion have been successful in decreasing renal cyst growth and in slowing the decline of renal
function in PKD [8–11]. Thus, treatment of mice, rats and humans with the vasopressin V2-re-
ceptor antagonist tolvaptan [12], crossing PKD rats (PCK strain) with vasopressin-deficient
rats (Brattleboro strain) [13], or increasing fluid intake in rats by adding glucose to the drinking
water [14] have all been effective to retard PKD disease progression. Patients with ADPKD
tend to have a higher urine output because of a renal concentrating defect and a blunted release
of vasopressin [15], but presumably also because drinking large amounts of water has been rec-
ommended to patients with ADPKD in an attempt to reduce cyst growth [16,17].
As mentioned, the aquaretic drug tolvaptan (vasopressin V2 receptor antagonist) was
shown to have beneficial effects on polycystic kidney disease progression. It is not known
whether the induction of osmotic diuresis would also have such a beneficial effect. We have
previously shown that the induction of osmotic diuresis by inhibiting renal proximal tubular
sodium-glucose cotransport (SGLT) with phlorizin retards cyst growth and renal functional
decline in the Han:SPRD rat model of PKD [18]. Phlorizin is a nonselective SGLT inhibitor
which inhibits SGLT1 and SGLT2. In recent years, selective SGLT2 inhibitors have been devel-
oped and are now in clinical use for the treatment of hyperglycemia in patients with type 2 dia-
betes mellitus [19]. To evaluate whether the selective inhibition of SGLT2 is capable of
retarding cyst volume progression and delaying renal functional loss, we tested the effect of
oral dapagliflozin (DAPA) administration in PCK rats, an orthologous model of ARPKD.
Materials and Methods
Ethics statement
All animal work was conducted according to relevant national and international guidelines.
The protocol was approved by the committee on the Ethics of Animal Experiments at the Uni-
versity of Zürich (Permit Number: 175–2012). All efforts were made to minimize any suffering
to animals.
Animals
PCK rats (an orthologous model of autosomal recessive polycystic kidney disease) and normal
Sprague-Dawley (SD) rats were used in this study. PCK rats (originally derived from SD rats)
were obtained from Charles River Laboratories (Sulzfeld, Germany) while SD rats were ob-
tained from the Rat Resource and Research Center (Columbia, MO, USA). All rats had free ac-
cess to tap water and were fed a standard rat diet. Only male rats were used in this study as
cysts develop more rapidly in male compared with female rats.
Experimental design
DAPA (Bristol-Myers Squibb, Princeton, New Jersey) was dissolved in a vehicle of polypropyl-
ene glycol, water and ethanol (45:45:10, v/v/v). At 5–6 weeks of age, male PCK or normal con-
trol SD rats (n = 8–9 per group) were given DAPA (10 mg/kg/d) or vehicle by gavage for 5–6
weeks. The doses of the drug and the vehicle were adjusted daily according to the body weight
of the rats. Blood was drawn and 24 h urine was collected at baseline and after 2–3 and 5–6
weeks of treatment to assess different parameters of renal function. At the end of the treatment
Dapagliflozin and Polycystic Kidney Disease
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phase (at 12 week of age), the PCK rats were examined by ultrasound to determine the kidney
and cyst volume in vivo. All rats were then sacrificed and the kidneys were excised, decapsu-
lated and weighed to calculate the two kidneys to total body weight (2K/TBW) ratios. Kidney
slices were fixed in 10% buffered formalin and were then embedded in paraffin for subsequent
histological examinations.
Plasma and urine analyses
Plasma and urine aliquots were rapidly frozen and stored at -80°C until their measurement.
Glucose, sodium, chloride, creatinine and blood urea nitrogen (BUN) concentrations were de-
termined in plasma and urine using a Cobas 8000 Modular Analyzer from Roche Diagnostics
AG (Rotkreuz, Switzerland). Plasma and urine osmolality were measured by using an Ad-
vanced Osmometer Model 2020 (Advanced Instruments Inc., Norwood, MA, USA). The urine
protein content was analyzed by SDS-PAGE and Coomassie blue staining, adjusting the load-
ing volumes of the samples to the 24 h urine volume. The GenWay rat albumin ELISA kit (San
Diego, CA, USA) was used to measure urine albumin concentration, according to the instruc-
tions provided by the manufacturer.
Ultrasound imaging of rat kidneys
PCK rats were anesthetized with isoflurane (1.5–2%) in oxygen. Physiological variables (heart
rate, respiratory rate, rectal temperature) were continuously monitored by using a VisualSonics
Advanced Physiological Monitoring Unit (Toronto, Ontario, Canada). The abdomen was
clipped and all hair was removed using Veet hair removal cream. Acoustic coupling was en-
sured using ultrasound coupling gel. Ultrasound images of the kidneys were acquired using a
high resolution ultrasound system (Vevo 2100, VisualSonics) equipped with a 18–38 MHz
probe (MS400). Following image optimization, transverse 2D and power Doppler images of
both kidneys were acquired with the aid of an automated 3D motor head. Care was taken to
include the cranial and caudal poles of the kidney where possible (maximum scan distance
28 mm). The slice thickness between scanning planes was 0.072 mm with a maximum of 500
slices. The images were captured in digital raw format (RF). Offline processing of 3D recon-
structions was performed using Vevo 2100 software (v1.6.0) on a dedicated workstation. The
resulting 3D model was used to determine the total kidney and cyst volumes and the number
of cysts.
Tissue sectioning, PAS staining, and cystic index determination
For histological examination, one of the kidneys from each rat was sliced perpendicularly to
the long axis at approximately 2 mm intervals. Slices from the midportion of the kidneys were
fixed in 10% buffered formalin overnight, and tissues were then embedded in paraffin.
Three μm sections were stained with periodic acid-Schiff (PAS) following a routine protocol.
The stained sections were subjected to cystic index analysis, using the HistoQuest image analy-
sis software (TissueGnostics, Vienna, Austria). The total kidney area (TKA) and the medullary
cystic area (MCA) were determined, and the cystic index was calculated in percent as MCA/
TKA100.
Immunohistochemical analysis
Immunohistochemistry for Ki67 was performed on 3 μm tissue sections which were deparaffi-
nized and rehydrated. Antigen retrieval was performed in an autoclave oven. Mouse anti-Ki67
antibody (BD Pharmingen, San Jose, CA, USA) was applied for 1 hour. Sections were washed
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and incubated with the biotinylated secondary antibody (Vector Laboratories Inc. Burlingame,
CA, USA) for 30 minutes. After washing, the ABC reagent (Vector) was applied to the sections
using 3,3’-diaminobenzidine with metal enhancement as the detection reagent. The percentage
of Ki-67 positive cells was determined from the total number of cells in cysts and non-cystic tu-
bules from each kidney section. We counted the total number of cells in 10 random fields con-
taining cysts and 10 random fields of non-cystic tissue in each kidney section of each PCK rat
using HistoQuest image analysis software (TissueGnostics, Vienna, Austria).
Determination of cAMP content of whole kidneys
The frozen kidneys were ground to fine powder under liquid nitrogen in a stainless steel mor-
tar. After the liquid nitrogen had evaporated, tissue was weighed and homogenized in 10 vol-
umes of 0.1 M HCl. After centrifugation at 600 g for 10 min at room temperature, the
supernatants were collected and assayed for cAMP without acetylation using an enzyme im-
munoassay kit (Sigma-Aldrich, Inc., St. Louis, MO, USA). The protein content was determined
by using the BCA protein assay kit from Pierce (Rockford, Illinois, USA). The results were ex-
pressed in pmol/mg of protein.
Statistics
Data are expressed as means ± SE. The individual parameters of the DAPA group were com-
pared with those of the CON group by a two-tailed Student’s t-test for unpaired data by using
the GraphPad Prism version 5.0 software (GraphPad, San Diego, CA, USA). Pvalues of < 0.05
were considered statistically significant.
Results
Effect of DAPA treatment on body weight, diuresis and electrolytes
Treatment with DAPA was well tolerated in PCK rats and they appeared healthy throughout
the 6 week treatment phase. Treatment of 6-week old male PCK rats with DAPA (10 mg/kg/d)
induced immediate and sustained glucosuria that was accompanied by a 2-fold increase in
water intake and a 3-fold increase in urine output when compared with vehicle-treated controls
(Table 1). Feces output was also increased by 23% at 3 week and by 45% at 6 week in DAPA-
treated PCK rats compared with controls. Plasma glucose (Pglucose) levels did not change in re-
sponse to DAPA, and plasma osmolality (Posm), sodium (PNa+) and chloride (PCl-) concentra-
tions remained stable at 3 and 6 weeks of treatment. DAPA-treated PCK rats displayed a
slightly enhanced urine sodium and chloride excretion rate compared with vehicle-treated rats.
Of note, DAPA-treated rats had a 6.4% lower body weight than controls at the end of the 6
week treatment phase (Table 1 and Fig 1A). Treatment with DAPA in normal SD rats also re-
sulted in the induction of glucosuria and an increase in water intake and urine output and a
slight increase in urine sodium and chloride, whereas PNa+ and PCl- remained stable (Table 2).
Effect of DAPA treatment on renal function and albuminuria
Table 3 shows that the plasma creatinine concentrations were similar at 3 weeks but tended to
increase at 6 weeks in DAPA-treated PCK rats. The plasma BUN concentrations were signifi-
cantly higher at 3 and 6 weeks of DAPA treatment. The clearances of creatinine and BUN were
significantly higher at 3 weeks, but the difference disappeared at 6 weeks of treatment with
DAPA. Calculating the [clearancecreatinine + clearanceBUN / 2] confirmed that there was a
higher clearance at 3 but not at 6 weeks of DAPA treatment in PCK rats (Fig 1B). Table 4
shows the data in normal SD rats. In DAPA-treated normal rats we did not see an increase in
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the creatinine and BUN clearances, and the [clearancecreatinine + clearanceBUN / 2] was also sim-
ilar between DAPA- vs. vehicle-treated SD rats. These data suggest that there was transient
hyperfiltration and subsequent deterioration of renal function upon treatment with DAPA in
PCK but not in SD rats.
Since albuminuria correlates with disease severity in PKD we analyzed the urine protein
content by SDS-PAGE and determined the urine albumin excretion by ELISA (Fig 2).
SDS-PAGE of urines (adjusted for 24 h urine volumes) revealed a marked increase of albumin-
uria in DAPA-treated PCK at 6 weeks (Fig 2A). The ELISA showed that albumin excretion
Table 1. Effect of DAPA on body weight, fluid balance and electrolytes in PCK rats.
Time point Baseline Day 21 Day 42
Treatment group CON DAPA CON DAPA CON DAPA
Number of animals 9 9 9 8 9 8
Age, week 6 6 9 9 12 12
Body weight, g 214 ± 5 210 ± 5 333 ± 5 324 ± 6 438 ± 6 410 ± 9*
Water intake, ml/d 31 ± 1 31 ± 1 48 ± 2 92 ± 2*** 40 ± 3 86 ± 8***
Diuresis, ml/d 10 ± 1 9 ± 1 18 ± 3 53 ± 2*** 19 ± 1 57 ± 7***
Posm, mosm/l 294.6 ± 2.2 293.8 ± 1.2 323.0 ± 2.4 315.4 ± 2.9 341.0 ± 7.5 351.6 ± 10.2
PNa+, mmol/l 137.6 ± 1.6 139.5 ± 0.6 138.5 ± 0.4 140.8 ± 0.4 140.9 ± 0.7 138.8 ± 2.5
PCl-, mmol/l 104.8 ± 0.8 105.5 ± 0.3 101.9 ± 0.5 103.9 ± 0.4 105.5 ± 1.6 104.0 ± 1.1
Pglucose, mmol/l 12.5 ± 1.4 10.6 ± 0.6 11.2 ± 0.4 11.3 ± 0.3 13.4 ±1.3 16.0 ± 2.7
Uosm, mosm/d 13.9 ± 0.7 14.2 ± 0.7 20.0 ± 2.1 57.2 ± 2.0*** 23.9 ±1.0 62.5 ± 5.6***
UNa+, mmol/d 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.5 ± 0.2* 1.2 ± 0.1 1.8 ± 0.1***
UCl-, mmol/d 2.0 ± 0.1 2.1 ±0.1 1.9 ±0.2 2.9 ± 0.2** 2.2 ± 0.1 3.3 ± 0.1***
Uglucose, mmol/d 0.1 ± 0.0 0.0 ± 0.0 0.3 ± 0.2 24.6 ± 0.9*** 0.3 ± 0.1 23.6 ± 4.3***
Data are expressed as means ± SE. CON, vehicle control; DAPA, dapagliflozin.
*P<0.05
**P<0.01
***P<0.001, when comparing DAPA and CON at each time point. P, plasma; U, urine.
doi:10.1371/journal.pone.0125603.t001
Fig 1. Effect of DAPA on body weight and renal function. Course of body weight in vehicle (CON) and dapagliflozin (DAPA) treated PCK rats during the 6
week treatment phase (A). [Clearancecreatinine + ClearanceBUN / 2] at baseline (BL) and after 21 and 42 days of treatment in PCK rats (B). N = 8 per group.
Data are expressed as means ± SE.*P<0.05.
doi:10.1371/journal.pone.0125603.g001
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increased slightly at 3 weeks and a further increase was observed at 6 weeks in vehicle-treated
PCK rats, as expected (Fig 2B). In DAPA-treated rats the albuminuria increased markedly at 3
weeks and more importantly at 6 weeks. After 6 weeks the albumin excretion amounted to
1.7 ± 0.3 mg/d in vehicle-treated rats and to 6.8 ± 0.7 mg/day in DAPA-treated animals
(P< 0.0001). In normal SD rats, the excretion of urine albumin was lower than in PCK rats but
also increased slightly upon treatment with DAPA for 5 weeks (0.4 ± 0.0 vs. 1.2 ± 0.2 mg/day,
P< 0.05).
In vivo high resolution ultrasound imaging of rat kidneys
After 6 weeks of treatment, the PCK rats were anesthetized for ultrasound analysis of both kid-
neys. Fig 3A shows that the kidneys with the typical medullary cysts could be easily visualized
Table 2. Effect of DAPA on body weight, fluid balance and electrolytes in normal SD rats.
Time point Baseline Day 18 Day 35
Treatment group CON DAPA CON DAPA CON DAPA
Number of animals 9 9 9 9 9 8
Age, week 5 5 7.5 7.5 10 10
Body weight, g 144 ± 2 149 ± 7 285 ± 5 297 ± 7 349 ± 5 354 ± 6
Water intake, ml/d 32 ± 1 32 ± 3 41 ± 2 54 ± 2*** 49 ± 3 62 ± 7*
Diuresis, ml/d 11 ± 1 12 ± 1 17 ± 2 24 ± 3* 32 ± 2 36 ± 4
PNa+, mmol/l 138.9 ± 0.4 142.3 ± 3.4 138.4 ± 0.4 133.5 ± 1.6* 141.9 ± 0.5 140.4 ± 0.6
PCl-, mmol/l 100.9 ± 0.3 100.6 ± 1.0 100.3 ± 0.3 94.0 ± 3.0 100.9 ± 0.3 95.9 ± 2.3
Pglucose, mmol/l 10.5 ± 0.6 10.3 ± 0.2 9.9 ± 0.2 9.7 ± 0.3 13.4 ± 0.2 13.0 ± 0.5
UNa+, mmol/d 1.3 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.4 ± 0.1 1.1 ± 0.3 1.6 ± 2.0
UCl-, mmol/d 2.1 ± 0.1 1.8 ± 0.2 1.8 ± 0.1 2.1 ± 0.1 2.3 ± 0.1 2.4 ± 0.5
Uglucose, mmol/d 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 10.6 ± 0.6*** 0.0 ± 0.0 13.5 ± 2.0***
Data are expressed as means ± SE. CON, vehicle control; DAPA, dapagliflozin.
*P<0.05
**P<0.01
***P<0.001, when comparing DAPA and CON at each time point. P, plasma; U, urine.
doi:10.1371/journal.pone.0125603.t002
Table 3. Effect of DAPA on renal function in PCK rats.
Time point Baseline Day 21 Day 42
Treatment group CON DAPA CON DAPA CON DAPA
Number of animals 9 9 9 8 9 8
Age, week 6 6 9 9 12 12
Pcreatinine, μmol/l 18.0 ± 0.0 18.0 ± 0.0 21.9 ±0.5 21.4 ±0.5 26.9 ± 1.2 36.1 ± 6.7
Clearancecreatinine, ml/min 2.4 ± 0.2 2.7 ± 0.2 2.6 ± 0.2 3.1 ±0.1* 3.2 ± 0.2 2.7 ± 0.3
PBUN, mmol/l 3.7 ± 0.1 3.9 ±0.1 4.1 ± 0.2 4.9 ± 0.2* 5.7 ± 0.1 7.1 ± 0.6*
ClearanceBUN, ml/min 1.0 ± 0.1 1.1 ± 0.1 1.2 ±0.1 1.7 ± 0.1** 1.3 ± 0.1 1.4 ± 0.1
[Clearancecreatinine + ClearanceBUN / 2] 1.7 ± 0.1 1.9 ± 0.1 1.8 ± 0.1 2.3 ± 0.1* 2.2 ± 0.1 2.0 ± 0.1
Data are expressed as means ± SE. CON, vehicle control; DAPA, dapagliflozin.
*P<0.05
**P<0.01, when comparing CON and DAPA at each time point. P, plasma.
doi:10.1371/journal.pone.0125603.t003
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in vehicle-treated male PCK rats. On the other hand, DAPA-treated rats displayed larger kid-
neys and had substantially bigger cysts (Fig 3B). Ultrasound-based measurements revealed a
35% higher total kidney volume (P< 0.01), a 2-fold higher cyst volume (P< 0.05) and a 47%
higher cystic index (P< 0.05) in DAPA- vs. vehicle-treated rats, whereas the number of cysts
was similar in both groups after 6 weeks of treatment (P= 0.841) (Fig 3C–3F).
Effect of DAPA treatment on kidney weight and morphology
After 6 weeks of treatment with DAPA the total weight of both kidneys was 23% higher in
DAPA- as compared with vehicle-treated male PCK rats (4.32 ± 0.24 vs. 5.33 ± 0.20 g,
P< 0.01). The two kidneys to body weight (2K/BW) ratio was also significantly increased by
34% in the DAPA-treated rats (P< 0.001). PAS-staining of kidney sections revealed that the
Table 4. Effect of DAPA on renal function in normal SD rats.
Time point Baseline Day 18 Day 35
Treatment group CON DAPA CON DAPA CON DAPA
Number of animals 9 9 9 9 9 8
Age, week 5 5 7.5 7.5 10 10
Pcreatinine, μmol/l 26.5 ± 0.0 26.5 ± 0.1 26.5 ± 0.0 26.5 ± 0.2 35.3 ± 2.5 35.3 ± 3.2
Clearancecreatinine, ml/min 1.7 ± 0.1 1.2 ± 0.3 2.0 ± 0.1 2.0 ± 0.2 2.6 ± 0.1 2.7 ± 0.2
PBUN, mmol/l 6.6 ± 0.3 5.5 ± 0.2 6.1 ± 0.2 8.2 ± 0.4*** 6.6 ± 0.1 9.9 ± 1.5*
ClearanceBUN, ml/min 0.6 ± 0.0 0.8 ± 0.1 0.8 ± 0.0 0.8 ± 0.1 1.1 ± 0.0 0.8 ± 0.2*
[Clearancecreatinine + ClearanceBUN / 2] 1.1 ± 0.1 1.0 ± 0.2 1.4 ± 0.1 1.2 ± 0.2 1.9 ± 0.1 1.9 ± 0.1
Data are expressed as means ± SE. CON, vehicle control; DAPA, dapagliflozin.
*P<0.05
**P<0.01
***P<0.001 when comparing CON and DAPA at each time point. P, plasma.
doi:10.1371/journal.pone.0125603.t004
Fig 2. Effect of DAPA on albumin excretion. Urine protein analysis by SDS-PAGE from urine samples of PCK rats after 6 weeks of treatment with vehicle
(CON) or dapagliflozin (DAPA). Each lane shows urine sample of a single PCK rat. Sample volumes were corrected for diuresis and amounted to 15 μl for
CON and 45 μl for DAPA. Arrow shows the band for albumin. M = molecular weight marker (A). Urine albumin concentration as measured by ELISA, in mg/
day (B). N = 8 per group. Columns represent means ± SE. **P<0.01, ***P<0.001 when comparing CON and DAPA at each time point, ns = non-significant.
doi:10.1371/journal.pone.0125603.g002
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cyst index was increased by 43% in DAPA-treated rats (P< 0.05) while the total cyst number
was not significantly changed (P= 0.074) (Figs 4 and 5). In normal SD rats the total kidney
weight of both kidneys was also higher in DAPA-treated rats as compared to the total kidney
weight in vehicle-treated rats (3.1± 0.3 vs. 2.3 ± 0.2 g, P= 0.0002).
Fig 3. Effect of DAPA on kidney volume and cystic index. Typical 2D transverse power Doppler ultrasound images of a kidney in CON- and DAPA-
treated PCK rats. The red areas represent a power Doppler signal consistent with blood flow within the renal vasculature. The maximum scan distance
between cranial and caudal poles of the kidney was 28 mm. The slice thickness between scanning planes was 0.072 mm with a maximum of 500 slices (A,
B). Change in kidney volume (C), cyst volume (D), cystic index (E) and number of cysts (F) in PCK rats. N = 6 rats or 12 kidneys per group. Columns
represent means ± SE. *P<0.05, **P<0.01, ns = non-significant.
doi:10.1371/journal.pone.0125603.g003
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Effect of DAPA treatment on renal cAMP content and renal epithelial cell
proliferation
Since cAMP is a major driver of cyst growth we analyzed the content of cAMP in PCK kidney
tissue by ELISA. Fig 6 shows that the amount of cAMP per mg of total protein was similar in
DAPA- and vehicle-treated male PCK rats (P= 0.717).
Immunohistochemistry staining for Ki67 was then used to examine whether DAPA treat-
ment had an effect on tubular and cystic epithelial cell proliferation. Fig 7 shows no significant
change in the number of Ki67-positive nuclei in the cystic epithelium in DAPA-treated PCK
rats. Quantification of the Ki67-positive nuclei confirmed that the number of Ki67-positive nu-
clei was not changed in cystic epithelium as well as in non-cystic epithelium in DAPA- vs. vehi-
cle-treated PCK rats (Table 5).
Discussion
Here we show that the induction of osmotic diuresis with the SGLT2-specific inhibitor DAPA
leads to an unexpected increase in the kidney and renal cyst volumes of PCK rats, an ortholo-
gous model of ARPKD. Furthermore, DAPA-treated PCK but not normal SD rats displayed a
transient increase in the clearances of creatinine and BUN and a progressive increase in albu-
minuria which suggests that DAPA promotes hyperfiltration in PCK rats. The renal cAMP
Fig 4. Effect of DAPA on kidney weight and cyst index. Ratio of two kidney weights to total body weight (2KW/TBW) (A), cyst index (B) and number of
cysts (C) after 6 week treatment with vehicle (CON) or DAPA in PCK rats. N = 8 per group. Columns represent means ± SE. *P<0.05, ***P<0.001, ns = non-
significant.
doi:10.1371/journal.pone.0125603.g004
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Fig 5. Effect of DAPA on renal histology. Representative renal histology by periodic acid-Schiff (PAS) staining of kidneys in vehicle- treated (CON) PCK
(A,E) and normal SD (C,G) rats and in DAPA-treated PCK (B,F) and normal SD (D,H) rats. Scale bar is 2000 μm in A and B and 500 μm in C and D.
doi:10.1371/journal.pone.0125603.g005
Fig 6. Effect of DAPA on renal cAMP content. Analysis of cAMP concentration per mg protein in PCK rat kidneys treated with vehicle (CON) or
dapagliflozin (DAPA). N = 8 per group. Columns represent means ± SE. ns = non-significant.
doi:10.1371/journal.pone.0125603.g006
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content was similar, and there was no evidence for heightened epithelial cell proliferation
which could explain the greater cyst volume upon treatment with DAPA. Thus, the induction
of glucosuria with DAPA appeared to have a negative impact on cystic disease progression in
PCK rats.
The increase in glomerular filtration in response to DAPA appeared to be transient, i.e. it
was seen after 3 weeks but not after 6 weeks. However it was associated with an increase in al-
buminuria at 3 weeks and a further increase at 6 weeks. In general, an increase in albuminuria
is seen with progressing stages of PKD [20]. The increased amount of urine albumin could be
Fig 7. Effect of DAPA on cell proliferation. Representative areas of Ki67 immunohistochemical staining in PCK rat kidneys are shown. Nuclei of
Ki67-positive cells were stained brown with 3,3’-diaminobenzidine and that of Ki67-negative cells appeared blue because of the counterstaining with
hematoxylin. CON (cystic area) (A), DAPA (cystic area) (B), CON (non-cystic area) (C), DAPA (non-cystic area) (D). Scale bar is 200 μm in A, B, C and D.
doi:10.1371/journal.pone.0125603.g007
Table 5. Effect of DAPA on cell proliferation in PCK rat kidneys.
Treatment CON DAPA Difference, % P-value
Number of animals 7 7
Ki67-positive cells (%) in cyst-lining epithelium 6.5 ± 1.3 6.7 ± 1.9 + 3.5 0.922
Ki67-positive cells (%) in non-cystic tubules 2.5 ± 0.91 3.1 ± 1.1 + 24.7 0.677
Morphometric analysis using Ki67, a proliferation marker in kidney medulla of vehicle (CON)- and DAPA-treated PCK rats. Data are expressed as
means ± SE.
doi:10.1371/journal.pone.0125603.t005
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the consequence of enhanced leakage of albumin from glomeruli, or alternatively it could be
caused by decreased tubular reabsorption. Whether albuminuria is reflecting glomerular
hyperfiltration damage needs to be examined further.
Treatment with SGLT2 inhibitors has been associated with a decrease in the GFR in normal
and diabetic rats and in humans with type 2 diabetes mellitus [21,22]. This contrasts with our
findings in PCK rats which display evidence of transient hyperfiltration. This hyperfiltration
could in part be explained by the enhanced food i.e. protein intake which is seen in response to
DAPA [23], since protein loading is a known stimulus for increasing glomerular filtration.
However this should have been counterbalanced by the higher sodium delivery at the macula
densa which normally leads to afferent arteriolar vasoconstriction [24]. Since normal rats
which are treated with DAPA do not develop hyperfiltration and albuminuria [25–27], the ef-
fects that we observed appear to be specific to the PCK model of PKD.
In a previous study, we found that treatment with the SGLT1/SGLT2 inhibitor phlorizin at-
tenuated albuminuria in Han:SPRD rats, improved GFR, and decreased cyst growth [18]. Con-
trasting with these results, the DAPA-treated PCK rats displayed enhanced cyst growth. Han:
SPRD rats are a non-orthologous model of PKD, with cyst formation exclusively in the proxi-
mal tubules [28,29]. In contrast, PCK rats display cyst formation in the distal nephron. Typical-
ly, the cysts disconnect from the original proximal tubule in Han:SPRD, whereas in PCK rats
the cysts remain connected to the distal tubule. We speculate that the increased intratubular os-
motic pressure which is caused by the glucosuria could promote the dilation of distal tubular
segments and cysts. This could cause compression of adjacent healthy distal tubules and pro-
vide a stimulus to enhance GFR, as it may be seen in partial obstructive uropathy [30].
The enhanced cyst growth did not appear to be the consequence of vasopressin-mediated
cAMP stimulation, since the renal cAMP content was similar between DAPA- and vehicle-
treated PCK rats. Despite a massive increase in the diuresis, DAPA-treated rats did not appear
to be dehydrated, and the serum sodium concentrations did not increase. This suggests indi-
rectly that vasopressin levels did not increase. Furthermore, Ki67 staining did not reveal an in-
crease in proliferating cells in dilated tubules, and there was no change in the number of nuclei
in the cysts upon DAPA treatment. This indicates again that the cysts increased in size due to
osmotic pressure without affecting epithelial cell proliferation.
Diabetes may occur in patients with ADPKD and it is associated with greater cardiovascular
morbidity [31]. With the possibility to treat ADPKD patients with SGLT2 inhibitors there
could be a risk of albuminuria and increased cyst growth. Although such a complication has
not yet been described caution should be exerted when prescribing these drugs to patients with
ADPKD.
In summary, we have shown that the induction of osmotic diuresis by inhibiting SGLT2
promotes transient hyperfiltration, albuminuria and increased cyst volume in PCK rats. Fur-
ther studies need to explore the mechanisms which link the enhanced glomerular filtration to
the increase in cyst volume upon SGLT inhibition in this model of PKD.
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Abst ract
Background/ Aims: The PCK rat model of polycystic kidney disease is characterized by the 
progressive development of renal medullary cysts. Here, we evaluated the suitability of high 
resolution ultrasonography (HRU) to assess the kidney and cyst volume in PCK rats, testing 
three different ultrasound image analysis methods, and correlating them with kidneys weights 
and histological examinations. Methods: After inducing anesthesia, PCK rats (n=18) were 
subjected to HRU to visualize the kidneys, to perform numeric and volumetric measurements 
of the kidney and any cysts observed, and to generate 3-dimensional images of the cysts 
within the kidney parenchyma. Results: HRU provided superior information in comparison to 
microscopic analysis of stained kidney sections. HRU-based kidney volumes correlated strongly 
with kidney weights (R2=0.809; P<0.0001). Conclusion: HRU represents a useful diagnostic 
tool for kidney and cyst volume measurements in PCK rats. Sequential HRU examinations 
may be useful to study the effect of drugs on cyst growth without the need to euthanize 
experimental animals.
Int roduct ion
Autosomal recessive polycystic kidney disease (ARPKD) has been estimated to have an 
incidence of 1:20,000 people and typically presents in utero or during the neonatal period 
with greatly enlarged, echogenic kidneys [1]. The disease is due to mutations in the gene 
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Pkhd1 which encodes for ibrocystin, a ciliary protein. The major histological manifestation 
is a fusiform dilatation of the collecting ducts where cysts are attached and do not separate 
from the parental tubules [2].
The PCK rat model is a well-known orthologous model of ARPKD that has been widely 
used to assess the therapeutic effect of drugs which retard cyst development in preclinical 
studies [3]. PCK rats develop multiple cysts in the renal medulla but not in the cortex. As the 
cysts grow the renal function deteriorates progressively, reducing the life span of the rats 
which generally die of renal failure.
A non-invasive imaging technique that is capable of high throughput, is relatively 
inexpensive and provides suficient resolution to quantify the variables of interest with high 
accuracy may reduce the number of experimental animals [4]. High-frequency ultrasound 
technology recently became more accessible, which enables high-quality imaging of 
anatomical structures in mice and rats, and provides excellent temporal and spatial 
resolution [5].
Here, we explored for the irst time if high resolution ultrasonography (HRU) is a 
suitable method to assess the cyst burden in anesthetized PCK rats. Ultrasonography was 
used to image PCK rat kidneys to determine total kidney volume (TKV), total cyst volume 
(TCV) and total cyst number (TCN). We compared 3 different methods for HRU-based TKV 
assessments, namely an HRU-stereological (HRUs), an HRU-automated (HRUa) and an HRU-
ellipsoid (HRUe) method and correlated the indings with total kidney weight (TKW) and 
histological examination (HE).
Materials and Methods
Experimental design
All animal experiments were conducted in an ethical and humane fashion, and were approved by 
the district veterinary ofice of the Canton Zurich (permit number 175-2012) that is our institutional 
animal care and use committee (IACUC). PCK rats (an orthologous model of autosomal recessive PKD) 
were obtained from Charles River Laboratories (Sulzfeld, Germany). Heterozygous Cy/ + Han:SPRD rats (a 
non-orthologous model of autosomal dominant PKD) and homozygous wild type +/ + rats were obtained 
from the Rat Resource and Research Center (Columbia, MO, USA). All animals were bred in our animal 
facility. Only male rats were used since cysts develop more rapidly in male than in female rats. PCK rats 
were examined at the age of 7 weeks (n=6) and 12 weeks (n=12) by HRU to determine their TKV, TCV and 
TCN. After HRU examination, the rats were euthanized and both kidneys were excised, decapsulated and 
weighed. Kidney slices of approximately 2 mm were then ixed in 10% buffered formalin and embedded in 
parafin for histological examination. Cy/ + Han:SPRD and wild type +/ + rats were examined at the age of 10 
and 12 weeks respectively to compare their renal HRU images with those of the PCK rats.
High Resolution Ultrasonography (HRU)
Animal preparation. Isolurane (5% induction, then 1.5-2% maintenance) in oxygen (1 L/ min) was 
used to induce and maintain anaesthesia. Physiological variables (heart rate, respiratory rate, rectal 
temperature) were continuously monitored during the procedure, using a physiological monitoring unit 
(VisualSonics, Toronto, Canada). As shown in Fig. 1A and 1B, rats were placed in dorsal recumbency and 
were ixed on a dedicated handling table for rats (VisualSonics) using adhesive tape. The abdomen of the 
rats was clipped and all hair was removed using hair removal cream (Veet).
Image acquisition
HRU images were acquired using the Vevo 2100 high resolution ultrasound system (VisualSonics) 
equipped with the 18-38 MHz probe (MS400) and 3-dimensional (3-D) image motor. Acoustic coupling 
was ensured using ultrasound coupling gel. Following image optimisation, kidneys were imaged in a 
ventro-dorsal plane to acquire sequential transverse 2-dimensional (2-D) and power Doppler images 
of each kidney, using an automated 3-D motor head and the respiratory gating feature to avoid artefacts 
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associated with respiratory motion. Care was taken to include the cranial and caudal poles of the kidney 
where possible (maximum scan distance 28 mm). The slice thickness between scanning planes was 0.05 
mm with a maximum of 500 frames. The images were captured in digital raw format as 500 frame cineloops. 
Following imaging, the rats were euthanized with embutramide (T61®) via injection into the liver. All raw 
data iles from HRU were copied to a work station and inspected to conirm complete coverage of both 
kidneys and image quality.
Image analysis
Stereological method. The 2-D transverse sequential cineloops were reconstructed into a rectangular 
3-D model, using the VevoLab v1.6.0 software (VisualSonics). Tracing of the outer kidney surface and the 
outer wall of each cyst was performed manually in the 3-D reconstruction, using the volume measurement 
tools present in the VevoLab software as per the manufacturer’s instructions. The resulting 3-D model 
was used to determine the stereological TKV (TKVs). Identiication and measuring of all cystic structures 
allowed the determination of the TCV and the TCN. Finally, cystic index (CI) was calculated in percent as 
TCVs/ TKVs*100.
Automated method. The 2-D transverse cineloops were exported from the VevoLab software and 
transferred to Analyze 12.0 software (AnalyzeDirect, Inc., Overland Park, KS, USA). Here, tracing of the 
kidney and cyst surface was performed in the 3-D reconstruction by semi-automatic tools present in 
the Analyze 12.0 software as per the manufacturer’s instructions. The resulting 3-D model was used to 
determine automated TKV (TKVa) and automated TCV (TCVa). The CI was again calculated in percent as 
TCVa/ TKVa*100.
Ellipsoid method. The 2-D and 3-D cineloops were used to determine the 3 renal dimensions (length, 
lateral diameter [width], anterior-posterior diameter [depth]). Renal length was determined from axial 
slices by multiplying the slice thickness by the number of slices between the cranial and caudal poles of 
the kidneys. Lateral diameter was measured from the lateral extent of the kidney to the renal sinus and 
Fig. 1. Experimental set-up using high resolution ultrasonography (HRU) for the analysis of kidney and cyst 
volumes in anaesthetized PCK rats.
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anterior-posterior diameter was measured perpendicular to the lateral diameter. The ellipsoid TKV (TKVe) 
was calculated using the ellipsoid formula (length × lateral diameter × anterior-posterior diameter × π / 6).
Histological analysis (HA) 
One of the kidneys from each rat was used for the histological analysis and was sliced perpendicularly 
to the long axis at approximately 2 mm intervals. Slices from the mid-portion of the kidneys were ixed in 
10% buffered formalin overnight, and tissues were then embedded in parafin. Three µm sections were 
stained with Periodic acid–Schiff (PAS) staining following a routine protocol. The stained sections were 
subjected to CI analysis, using the HistoQuest image analysis software (TissueGnostics, Vienna, Austria). 
We calculated the total cystic and total kidney area in six full cross sections of each kidney and averaged 
the total cystic area (TCA) and total kidney area (TKA) in each PCK rat. The CI was calculated in percent as 
TCA/ TKA*100.
Statistical analysis
Data are expressed as means ± SD. Different age groups were compared with two-tailed Student’s 
t-test for unpaired data by using the GraphPad Prism version 5.0 software (GraphPad, San Diego, CA, USA). 
Bland–Altman plot and Pearson correlation test were used to show the differences in TKVs vs TKVa, TKVs vs 
TKVe, TKW vs TKVs and TKW vs TKVa. P values of <0.05 were considered statistically signiicant.
Results
TKV, TCV and TCN determination by stereological method
We performed HRU on 7- and 12-week old PCK rats (Fig. 2A and 2B), 10-week old 
heterozygous Cy/ + Han:SPRD rats (Fig. 2C) and 12-week old wild type +/ + rats (Fig. 2D). The 
kidney cysts were readily visible in 7- and 12-week old PCK rats. In Cy/ + Han:SPRD rats, the 
kidneys appeared to be enlarged compared with +/ + wild-type rats. Furthermore, the renal 
cortex showed an increased echogenicity in Cy/ + compared with +/ +. Contrasting with PCK, 
individual cysts could however not be identiied in Cy/ + kidneys, which is in line with the 
Fig. 2. Represen-
tative transverse 
2-dimensional (2-
D) B-mode images 
of the right kidney, 
overlaid with pow-
er Doppler (red 
areas) to identify 
blood low within 
the renal paren-
chyma in 7-week 
old PCK rat (A), 12-
week old PCK rat 
(B), 10-week old 
Cy/ + (Han:SPRD) 
rat (C) and 12-
week old wild-type 
(+/ +) rat (the latter 
is a 2-D B-mode 
image without 
power Doppler) 
(D).
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Table 1. HRU-based stereological analysis of kidney and cyst volume in 7- and 12-week old PCK rat kidneys
known histological observations. Thus, the PCK model appeared suitable for determining 
the TCV and TCN in addition to TKV by HRU, whereas in the Cy/ + only the TKV could be 
determined.
Thus, we then focused on PCK rats to determine TKV, TVC and TCN in 7- and 12-week 
old rats by the stereological image analysis method (Table 1). As expected, there was a 
signiicant increase in TKVs with age from 3322 ± 345 mm3 at 7 weeks to 4554 ± 653 mm3 
at 12 weeks (P=0.0009), whereas the TCVs (180 ± 50 vs 198 ± 44 mm3; P=0.4861), the TCNs 
(60 ± 4 vs 64 ± 16; P=0.6048) and the CI (5.4 ± 1.3 vs 4.4 ± 1.0%; P=0.0786) did not change 
between 7- and 12- weeks of age.
Altogether our indings demonstrate that TKVs, TCVs and TCNs can easily be measured 
by HRU in the PCK rat model, whereas HRU only allows to determine TKVs in the Cy/ + rat 
model because the cysts are too small to be detected by HRU.
TKV determination by automated and ellipsoid methods
We then determined the TKV by the automated (TKVa) and the ellipsoid (TKVe) method 
in 7- and 12-week old PCK rats, as well as in 10-week old Cy/ + Han:SPRD rats, and compared 
the values to the stereologically determined TKVs. These volumes were then correlated with 
the TKW which was obtained after euthanizing the animals. The time needed to measure 
TKVs was 20-30 minutes per animal, compared with 15-20 minutes for TKVa and 10-12 
minutes for TKVe. Table 2 shows that the TKV analyzed by these three methods showed 
similar values, but with highest value for TKVs followed by TKVa and TKVe in 7-weeks old 
(3322 ˃3141˃2937 mm3) and in 12-weeks old (4554 ˃4308˃3871 mm3) PCK rats as well 
as in 10-weeks old (6610˃6442˃6035 mm3) Cy/ + rats. The TKV detected by these three 
methods (TKVs, TKVa, and TKVe) were also in good agreement with the TKW (Table 2). 
67
 Kidney Blood Press Res 2016;41:186-196
10.1159/000443420
Published online: March 17, 2016
©  2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 191
Kapoor/Rodriguez/Mitchell/Wüthrich: Ultrasonography and Polycystic Kidney Disease
Fig. 3A and 3C show that there was a strong 
correlation of TKVs with TKVa (R2=0.991, P<0.0001) 
and TKVe (R2=0.966, P<0.0001) in PCK rats (n=18). 
The corresponding Bland-Altman plots (Fig. 3B and 
3D) show that the TKVs exceeds the TKVa by 5.6 ± 
2.1% (95% conidence interval, 1.5% to 9.9%) and 
the TKVe by 15.0 ± 3.8% (95% conidence interval, 
7.6% to 22.4%). In Cy/ + rats (n=5) we also found 
a strong correlation of TKVs with TKVa (R2=0.973, 
P=0.0019) and TKVe (R2=0.999, P<0.0001) (graphs 
not shown).
TKV correlation with TKW
We then correlated TKVs and TKVa with 
TKW (Fig. 4A and 4B). TKW correlated well with 
TKVs (R2=0.809, P<0.0001) and TKVa (R2=0.782, 
P<0.0001) in PCK rats (n=18). The TKW (in 
mg) exceeded TKVs and TKVa (in mm3) which is 
consistent with the speciic weight of kidney tissue 
that is higher than water. In Cy/ + rats (n=5) the 
TKW also correlated well with TKVs (R2=0.961, 
P=0.0033) and TKVa (R2=0.940, P=0.0176) (graphs 
not shown).
Comparison of HRU with histological analysis 
(HA)
Using HA, the cyst burden in the PCK model can 
be estimated by CI determination which is calculated 
by dividing TCA with TKA and multiplying by 100. 
We were interested to determine the correlation 
of this area-based CI by HA with the volume-
based CI which is obtained by HRUs and HRUa by 
dividing the TCV with TKV, multiplied by 100. The 
CI was signiicantly higher by HA in comparison to 
HRUs- and HRUa-based CI in 7- and 12- week old 
PCK rats (Table 3). Fig. 5A and 5B illustrate the 
histological view in a 7- and a 12-week old PCK 
rat and demonstrate the cyst growth between 7- 
and 12- weeks. Fig. 5C shows that the correlation 
between the area-based CI and the volume-based CI 
was weak (R2=0.026, P=0.5247) (n=18). 
3-D reconstruction from HRU
We inally generated 3-D reconstructions of 
HRU images which were acquired from PCK rat 
kidneys. Fig. 6A shows the tracings of the outer 
kidney and cyst wall used for the inal reconstruction 
of the kidney and all cysts. Fig. 6B illustrates the 
types of 3-D images that can be obtained, revealing 
excellent spatial resolution of the cysts within the 
renal parenchyma in PCK rats (see also video clip of 
3-D reconstructed kidney with cysts in a 12-week 
old PCK rat shown at the right QR-Code).
Table 2. Comparison of total kidney vol-
umes as determined by stereological 
(TKVs), automated (TKVa) and ellipsoid 
(TKVe) methods with total kidney weight 
(TKW) in 7- and 12-week old PCK rats and 
in 10 weeks old Cy/ + Han:SPRD rats
Video clip. Video 
clip of 3-D recon-
structed kidney 
with cysts in a 12-
week old PCK rat.
68
 Kidney Blood Press Res 2016;41:186-196
10.1159/000443420
Published online: March 17, 2016
©  2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 192
Kapoor/Rodriguez/Mitchell/Wüthrich: Ultrasonography and Polycystic Kidney Disease
Discussion
In this study, we tested the utility of HRU in two different rat models of PKD, the PCK 
and the Han:SPRD rats. HRU allowed to visualize renal cysts and to determine the kidney and 
cyst volume and the number of cysts in PCK rats, whereas HRU did not allow to visualize the 
cysts in the Han:SPRD rat model of PKD since the cysts are too small to be visualized with 
the 18-38 MHz ultrasound probe. Nevertheless, the kidney volumes could be determined by 
HRU in Han:SPRD rat. Thus, the method could therefore be useful to follow kidney volume 
changes over time as well as in response to experimental therapies.
Fig. 3. Correla-
tion of stere-
ological total 
kidney volume 
(TKVs) with au-
tomated total 
kidney volume 
(TKVa) (A and 
B) and with 
ellipsoid total 
kidney volume 
(TKVe) (C and 
D) in 7- and 12-
week old PCK 
rats (n=18).
Fig. 4. Correla-
tion of total 
kidney weight 
(TKW) with 
s t e r e o lo gica l 
total kidney 
volume (TKVs) 
(A) and with 
automated to-
tal kidney vol-
ume (TKVa) (B) 
in 7- and 12-
week old PCK 
rats (n=18).
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Among the three different types of HRU-based 
volumetric measurements (stereological, automated 
and ellipsoid) the stereological method was the most 
time consuming. Assuming that TKVs might provide 
the most precise volume measurements, the TKVa and 
the TKVe appeared to systematically underestimate the 
“true” TKV. All three methods correlated well with each 
other, and also with kidney weights. HRU also allowed 
accurate quantiication of the number of cysts in each 
kidney, a parameter that cannot be obtained with the 2-D 
histological analysis that is unable to represent the entire 
kidney.
The HRU-based cyst volume determinations yielded 
cystic indices (CI) which did not correlate with the indices 
obtained by histological analysis. Assuming a more precise 
estimation of the cyst burden by determining the CI with 
the volumetric method, we believe that HRU improves 
precision over the histological method. This may be 
particularly relevant for experimental research which 
tests novel drugs to retard PKD disease progression.
PKD research has increased exponentially in the last 
three decades and has led to the development of several 
candidate drugs to prevent disease progression (i.e. cyst 
growth). Recent clinical trials with some of these drugs 
provided modest but encouraging results. However the 
management of most patients with ADPKD continues to 
be restricted to the detection and treatment of renal and 
extra-renal complications, and timely initiation of renal 
Table 3. HRU-based cystic index 
(CI) determination using stere-
ological (HRUs) and automated 
(HRUa) method, and comparison 
with histological analysis (HA)-
based CI in 7- and 12- week old 
PCK rats
Fig. 5. Detection of cysts in male PCK rats by histology using Periodic acid–Schiff (PAS) staining in 7-week 
old (A) and 12-week old (B) PCK rats. Correlation of areal cystic index (%) obtained from histological anal-
ysis (HA) with volumetric cystic index (%) obtained from high resolution ultrasonography (HRU) using 
stereological method (HRUs) in PCK rats (C) (n=18).
replacement therapy which includes dialysis and transplantation [6]. The PCK rat represents 
a reliable experimental model of PKD that has been widely used to evaluate the eficacy of 
pharmacological interventions designed to ameliorate PKD. Thus, several drugs have been 
tested in PCK rats, including vasopressin V2 receptor antagonists which were shown to be 
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effective in reducing cyst growth and slowing the decline of kidney function [7-9]. Other 
examples include chronic water loading which also ameliorated the renal pathology by 
an inhibition of vasopressin secretion [10] and the somatostatin agonists octreotide and 
pasireotide [11, 12]. In all these studies disease progression was monitored by histological 
analysis and not by ultrasound imaging. HRU offers the advantage over histological analyses to 
be more accurate and to be used repetitively without the need to euthanize the experimental 
animals. In previous studies, we examined the effect of dapaglilozin, an inhibitor of the renal 
sodium-glucose cotransporter 2 (SGLT2), in Han:SPRD [13] and in PCK rats [14] and found 
quite surprisingly that the drug had opposing effects. In PCK rats we evaluated the utility 
of HRU and found that HRU was very robust in evaluating the effect of the drug. Based on 
our results, we therefore recommend HRU in the PCK rat strain to precisely monitor cyst 
progression and to study the effect of novel drug therapies.
Our study is extending data from another study where it was shown that volume changes 
in the rat kidney can be measured in vivo with 3-D ultrasound using a position sensor [15, 
16]. Furthermore, ultrasonography examination was shown to be useful and reliable for 
diagnosing PKD in cats with polycystic kidney [17-19]. It has also been shown that the 
resistive index which measures the arterial resistance in the peripheral vessels by Duplex-
ultrasound is a valuable diagnostic tool to detect renal diseases in cats [20]. It is only by the 
HRU method however that intrarenal cysts can be visualized in rats. HRU therefore opens 
new possibilities for measurements of the volumes of organs in small animals such as rats.
As there is a great need to reduce the number of experimental animals, HRU might 
contribute to using a lower number of rats when examining cyst progression in PCK rats, 
since HRU offers sequential visualization of the cystic disease process in these rats over time. 
Thus, PCK rat kidneys can be examined at various intervals along a given treatment time, 
allowing dose adaptations and treatment prolongations without the need to sacriice the 
experimental animals. In addition, since PCK also suffer liver disease, the HRU technique 
could also be used for sequential liver volume measurements. Thus, additional information 
can be gained in a single experimental animal with the advantage of a potentially lower 
number of rats.
In summary, we have shown that HRU is a very useful tool for measuring kidney and 
cyst volume in the PCK rat model of ARPKD, facilitating future pharmacological studies and 
offering the advantage to use a lower number of experimental animals.
Fig. 6. A 3-dimensional (3-D) reconstruction from a PCK rat kidney showing the tracings of the outer cyst 
wall used for the inal reconstruction (A), allowing visualisation of the kidney and the intra-parenchymal 
cysts and their spatial orientation (B).
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Abstract
Dysregulated signaling cascades alter energy metabolism and promote cell proliferation
and cyst expansion in polycystic kidney disease (PKD). Here we tested whether metabolic
reprogramming towards aerobic glycolysis (“Warburg effect”) plays a pathogenic role in
male heterozygous Han:SPRD rats (Cy/+), a chronic progressive model of PKD. Using
microarray analysis and qPCR, we found an upregulation of genes involved in glycolysis
(Hk1, Hk2, Ldha) and a downregulation of genes involved in gluconeogenesis (G6pc, Lbp1)
in cystic kidneys of Cy/+ rats compared with wild-type (+/+) rats. We then tested the effect of
inhibiting glycolysis with 2-deoxyglucose (2DG) on renal functional loss and cyst progres-
sion in 5-week-old male Cy/+ rats. Treatment with 2DG (500 mg/kg/day) for 5 weeks
resulted in significantly lower kidney weights (-27%) and 2-kidney/total-body-weight ratios
(-20%) and decreased renal cyst index (-48%) compared with vehicle treatment. Cy/+ rats
treated with 2DG also showed higher clearances of creatinine (1.98±0.67 vs 1.41±0.37 ml/
min), BUN (0.69±0.26 vs 0.40±0.10 ml/min) and uric acid (0.38±0.20 vs 0.21±0.10 ml/min),
and reduced albuminuria. Immunoblotting analysis of kidney tissues harvested from 2DG-
treated Cy/+ rats showed increased phosphorylation of AMPK-α, a negative regulator of
mTOR, and restoration of ERK signaling. Assessment of Ki-67 staining indicated that 2DG
limits cyst progression through inhibition of epithelial cell proliferation. Taken together, our
results show that targeting the glycolytic pathway may represent a promising therapeutic
strategy to control cyst growth in PKD.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal
disease, characterized by progressive development of innumerable cysts in both kidneys. The
development and relentless growth of cysts lead to kidney enlargement and compression of
renal parenchyma, leading to subsequent loss of renal function [1,2]. Recent studies have indi-
cated that various signaling cascades are dysregulated in ADPKD, including activation of
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mTOR and downregulation of AMPK signaling, and enhanced vasopressin-mediated cAMP
and ERK signaling [3,4,5,6]. Favourable results from several clinical trials targeting these path-
ways have led to the development of therapeutic concepts for ADPKD, yet treatment is not
available for the majority of patients [7].
A promising strategy to achieve therapeutic selectivity and efficacy in ADPKD is to take
advantage of the fundamental difference between cyst epithelial cells and normal epithelial
cells in their energy metabolism. A recent study by Rowe et al. has shown that glycolysis was
enhanced in a mouse model of ADPKD and also in kidney tissues from patients with ADPKD
[8]. Metabolomic profiling of extracellular medium of embryonic fibroblast cultures derived
from Pkd1-/- and Pkd1+/+ mice indicated increased glucose uptake and lactate production and
enhanced glycolytic enzyme gene expression in the mutant cells [8]. Using 2-deoxyglucose
(2DG), an analog of glucose that blocks glycolysis, they found that cyst growth could be inhib-
ited in rapidly progressing mouse models of polycystic kidney disease (PKD). Although the
tested models did not allow for assessment of renal function, the data suggested that targeting
glycolysis might represent a novel therapeutic strategy in ADPKD.
The purpose of the present study was to extend the above observations and to examine
whether 2DG could be used in a chronic progressive rat model of PKD. Here we show that cys-
tic kidneys in Han:SPRD rats display metabolic reprogramming in the sense of a ‘Warburg
effect’ and that 2DG improved renal functional loss and cyst progression through normaliza-
tion of intracellular signaling pathways.
Methods
Animals
The Han:SPRD rat colony was established in our animal facility from a litter which was
obtained from the Rat Resource and Research Center (Columbia, MO, USA). Heterozygous
cystic (Cy/+) and wild type normal (+/+) rats were used in this study. Han:SPRD rats carry a
missense mutation in Anks6 (also called Pkdr1), leading to an R823W substitution in SamCys-
tin, a protein that contains ankyrin repeats and a sterile alpha motif (SAM) [9]. Han:SPRD Cy/
+ rats develop a slowly progressing form of PKD which resembles phenotypically human
ADPKD [10]. Only male rats were used in this study since cysts develop more rapidly in male
compared with female rats [11]. The protocol has been approved by the committee on the Eth-
ics of Animals Experiments at the University of Zurich (Licence Number: 174–2013). Rats had
free access to tap water and standard rat diet.
Genechip expression analysis
Affymetrix GeneChip1 rat genome 230 2.0 arrays were used according to the manufacturer's
instructions (Affymetrix Inc., Santa Clara, CA, USA). Briefly, 5 μg of total RNA from 5-week old
Cy/+ and +/+ rat kidneys was used as starting material to generate biotin-labeled cRNA samples,
which includes cDNA synthesis using oligo-dT/T7 primers, followed by in vitro transcription
(one-cycle labeling protocol). Labeled cRNA samples (15 μg) were randomly fragmented to 35–
200 bp and hybridized on arrays for 16 h. After washing the arrays the fluorescent intensity emit-
ted by the labeled targets was measured by an Affymetrix GeneChip1 Scanner 3000. Finally, the
hybridization images were analyzed using Affymetrix GCOS1.2 software.
Reverse transcription and real-time PCR
RT-PCR analyses were performed as described previously [12,13]. Total RNA was reverse-
transcribed and PCR was carried out using SYBR1 Green JumpStart Taq ReadyMix (Sigma-
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Aldrich, St Louis, MO, USA). Real-time PCR analyses were performed with the ABI PRISM
7500 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland), according to
the instructions of Applied Biosystems. The expression levels of β-actin were used as a house-
keeping gene. Relative quantification of all targets was calculated by the comparative cycle
threshold method outlined by the manufacturer (User Bulletin No. 2; Applied Biosystems,
Rotkreuz, Switzerland).
Experimental protocol
Male Cy/+ and +/+ rats were weaned and then treated at 5 weeks of age with 500 mg/kg/day
2DG (Cy/+: n = 10; +/+: n = 10) or vehicle NaCl (Cy/+: n = 10; +/+: n = 10) by daily subcutane-
ous injection for 5 weeks throughout the treatment phase. The dose of 2DG or vehicle was
adjusted daily to the body weight of the rats. For blood collection, rats were anesthetized with
inhalation of 1.5–3.5% isoflurane. Metabolic cages were used to collect 24-hour urine samples
and to monitor food and fluid intake. Rats were acclimatized to the metabolic cage for an hour
every day for three consecutive days prior to the actual metabolic cage experiment. All animals
were sacrificed at week 10 by CO2 euthanasia.
Blood and urine chemistries
Plasma and 24-hour urines were collected from rats at week 5, 7.5 and 10 and aliquots were
rapidly frozen and stored at -80°C until measurement. Glucose, sodium, chloride, creatinine,
blood urea nitrogen (BUN) and uric acid concentrations were determined in plasma and urine
using a Cobas 8000 Modular Analyzer from Roche Diagnostics AG (Rotkreuz, Switzerland).
Plasma and urine osmolality were measured by using an Advanced Osmometer Model 2020
(Advanced Instruments Inc., Norwood, MA, USA). Urinary albumin concentration was deter-
mined using a rat albumin ELISA kit (Genway, San Diego, CA, USA), as previously described
[14]. Albuminuria was expressed as total urinary albumin excretion over 24-hour. Urine pro-
teins were also analyzed by non-reducing SDS-PAGE and Coomassie blue staining.
Tissue processing, periodic acid-Schiff staining, and cyst index
measurement
At the age of 10 weeks, all rats were sacrificed and kidneys were excised, decapsulated and
weighed. For histological examination, one of the kidneys from each animal was sliced perpen-
dicularly to the long axis at approximately 2 mm intervals. Slices from the midportion of the
kidneys were fixed in 4% buffered formalin and submitted to subsequent paraffin embedding.
Serial sections of 3 μm thickness per paraffin block were cut and stained with periodic acid-
Schiff (PAS) following a routine protocol. The stained sections were subjected to cyst index
analysis, using the HistoQuest image analysis software (TissueGnostics, Vienna, Austria) to
determine the cyst area (CA) and the total area (TA). The cyst index was calculated as CA/
TA100.
Immunohistochemical detection of proliferation
Immunohistochemistry for Ki67 was performed on 3-μm tissue sections. In brief, the tissue
sections were deparaffinized and rehydrated. The antigen retrieval was performed in an auto-
clave oven. Primary mouse anti-Ki67 antibody (BD Pharmingen, San Jose, CA, USA) and bioti-
nylated secondary antibody (Vector, Los Angeles, CA, USA) were used. This was followed by
the application of the ABC reagent, using 3,3’-diaminobenzidine with metal enhancement as
the detection reagent. The stained sections were subjected to analysis using the HistoQuest
Glycolytic Inhibition in PKD
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image analysis software (TissueGnostics, Vienna, Austria) to quantify the number of Ki67-po-
sitive nuclei over the total area of the kidney section.
Primary TEC cultures
Primary cultures of renal tubular epithelial cells (TECs) from 10-week-old +/+ and Cy/+ kid-
neys were prepared by mincing the kidneys and digesting the tissues with 1 mg/ml collagenase
with gentle agitation for 1 h at 37°C. The suspension was allowed to sediment for 1 min. Cells
were collected by harvesting the supernatant twice, and were then washed three times with
10% fetal bovine serum (FBS)/Hanks balanced salt solution. Isolated cells were resuspended in
K1 medium (1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium
supplemented with 5% FBS, 10 mmol/l HEPES, 42 mmol/l sodium bicarbonate, 50 ng/ml insu-
lin, 50 nmol/l hydrocortisone, 50 ng/ml transferrin, 5 pmol/l triiodothyronine, 20 ng/ml rat
EGF, 100 IU/ml penicillin, and 100 μg/ml streptomycin). Cells were then seeded in collagen
type 1–precoated culture dishes and grown to confluence. The medium was changed to a K1
medium with 0.5% FBS for 24 h, and the cells were then incubated with 2DG at various con-
centrations for 24 h. Cell viability was assessed by MTS assay following standard protocols.
Normal human kidney epithelial cells (NHK) were obtained from ATCC (ATCC1 PCS-
400-010™, Manassas, VA, USA). ADPKD cells were prepared from nephrectomy material as
previously described [15], after obtaining ethical approval from the ethics committee of the
canton of Zurich, Switzerland, and informed oral consent. The culture conditions for ADPKD
and NHK cells were similar to that of rat primary renal tubular epithelial cells.
Western blotting analysis
Snap frozen kidney tissue was homogenized and tissue lysates or cell culture lysates were
resolved by SDS–polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes,
and probed with primary antibodies. Mouse anti-Phospho-p70-S6K (Thr389), rabbit anti-
p70-S6K mouse anti-Phospho-Erk1/2 (Thr202/Tyr24), rabbit anti-Erk1/2, rabbit anti-Phos-
pho-AMPKα (Thr172), mouse-anti-Phospho-Akt (Ser473), rabbit anti-Akt and anti-caspase-3
antibodies were obtained from Cell signaling Technology, Beverly, MA, USA. Mouse anti-
AMPKα was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-mouse
and anti-rabbit secondary antibodies were purchased from Licor Biosciences (Lincoln,
Nebraska, USA).
ATP and lactate quantification
Intracellular ATP was quantified by luciferase activity according to the standard protocol in
the ATP Determination kit (Invitrogen, Life Technologies, Zug, Switzerland). The concentra-
tion of lactate in cell culture supernatants and in kidney tissue from Han:SPRD rats was mea-
sured using the EnzyChrom L-lactate Assay Kit (BioAssay Systems, Hayward, USA), according
to the manufacturer’s instructions.
In vitro BrdU Proliferation Assay
In vitro proliferation of primary TEC was analyzed with the colorimetric cell proliferation
BrdU assay kit (Roche Applied Science, Indianapolis, USA) according to the manufacturer’s
instruction. Briefly, cells were cultured in 96-well plates with or without 2DG. After 48 hours,
cells were labeled using 10 μM BrdU per well and re-incubated overnight at 37°C in a humidi-
fied atmosphere. The next day, the culture media was removed, the cells were fixed, and the
DNA was denatured in one step by adding FixDenat solution. Cells were incubated with anti-
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BrdU-POD antibody, washed and the substrate solution was added. The reaction product was
quantified by measuring the absorbance using a spectrophotometer at 370 nm with a reference
wavelength of 492 nm.
In vitro Cell Apoptosis Assay
Cells were cultured in 6-well plates with or without 2DG at a concentration of 1, 5, and 10 mM.
After 24 hours, cells were collected following detachment with trypsin, resuspended in 140
mM NaCl, 10 mM HEPES, and 2.5 mM CaCl2 and incubated with annexin V-FITC (Roche
Diagnostics, Basel, Switzerland) for 30 minutes at room temperature according to the manufac-
turer’s instructions. Flow cytometric analyses were performed using a BD-FACScan flow
cytometer (BD Biosciences, San Jose, CA, USA). Data were analyzed using FlowJo software
(Treestar Inc., Ashland, OR, USA.).
Statistical analyses
All data are expressed as means ± SEM unless otherwise stated. Statistical analyses were per-
formed using Student’s-t-test and ANOVA with Dunnett post-hoc test for multiple comparison
analysis using GraphPad Prism version 5.0 (Graph Pad Inc., San Diego, CA, USA). A value of
P< 0.05 was considered as statistically significant.
Results
Increased glycolysis and decreased gluconeogenesis in polycystic
kidney disease
First we performed microarray gene expression analysis on mRNA transcripts from kidney tis-
sues from Han:SPRD Cy/+ and wild-type +/+ male rats to examine the glycolysis and the glu-
coneogenesis pathways of glucose metabolism. The microarray results are available online
(accession number GSE75578) at the NCBI Gene Expression Omnibus (GEO). The mRNA lev-
els of several genes involved in the glycolysis pathway were upregulated, whereas transcript lev-
els of genes encoding for enzymes in gluconeogenesis were significantly donwregulated (Fig 1A
and 1B). This observation was confirmed by quantitative real-time PCR analysis which demon-
strated upregulation of key genes involved in the glycolysis pathway (Hk1, Hk2, Ldha) and
downregulation of key genes involved in the gluconeogenesis pathway (Fbp1, Fbp2, G6pc) in
the kidney tissues of Cy/+ rats versus +/+ rats (Fig 1C). Furthermore, upregulation of Hk1 and
Hk2 genes was also observed in primary cell cultures of human ADPKD as compared to con-
trol primary cultures of normal human kidney (NHK) epithelial cells (Fig 1D).
To extend these observations we measured the intracellular ATP levels and the production
of lactate in vitro using primary cell cultures of tubular epithelial cells isolated from kidneys of
Cy/+ versus +/+ rats. The intracellular ATP levels were significantly increased in the Cy/+ cell
cultures as compared to +/+ cell cultures, and were decreased upon incubation of Cy/+ cells
with 2DG (Fig 2A). Furthermore, the lactate content in the cell culture media was higher in
Cy/+ cell cultures in comparison to +/+ cell cultures, and was also decreased upon incubation
of Cy/+ cells with 2DG (Fig 2B). No significant changes in the intracellular ATP levels or lac-
tate content in the cell culture media were observed when +/+ cells were incubated with 2DG
(Fig 2A and 2B). Similar observations were obtained in the primary cell cultures of human
ADPKD and NHK cells; intracellular ATP levels and lactate in the cellular medium were higher
in ADPKD cells as compared to NHK cells, and the levels were diminished upon incubation of
ADPKD cells with 2DG (Fig 2D and 2E).
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Fig 1. Dysregulation of the glycolysis and gluconeogenesis pathways in rat polycystic kidney disease. (A) Microarray analysis showing differential
expression of genes coding for glycolysis and gluconeogenesis enzymes in Han:SPRD Cy/+ and wild-type +/+ kidneys. Upregulated genes are shown in red,
and downregulated genes are shown in green. (B) Schematic diagram showing the glycolysis/gluconeogenesis cascades. In red, upregulated genes; green,
downregulated genes; black, genes unchanged in kidneys from Cy/+ rats compared with wild-type +/+ kidneys. (C) Real-time quantitative PCR analysis of
genes coding for key enzymes involved in glycolysis/gluconeogenesis in kidneys from Cy/+ rats and +/+ rats. (D) Real-time quantitative PCR analysis of the
hexokinase-1 (Hk1) and hexokinase-2 (Hk2) genes in primary cell cultures of human ADPKD and control NHK cells. The expression levels of β-actin were
used as a housekeeping gene.
doi:10.1371/journal.pone.0146654.g001
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Fig 2. Increased glycolytic phenotype in polycystic kidney disease. (A) Intracellular ATP content in primary cell cultures of tubular epithelial cells
isolated from kidneys of Cy/+ and +/+ rats. (B) Lactate concentration in the medium of primary cell cultures of tubular epithelial cells isolated from kidneys of
Cy/+ and +/+ rats. (C) Cell growth of primary renal Cy/+ cells upon incubation with increasing concentrations of 2DG, as assessed by the MTS assay. (D)
Intracellular ATP content in primary cell cultures of ADPKD and NHK cells. (E) Lactate concentration in the medium of primary cell cultures of ADPKD and
NHK cells. (F) Effect of 2DG on cell proliferation of human ADPKD cells and control NHK cells, as quantified by BrdU assay. (G) Effect of 2DG on apoptosis
of human ADPKD cells and control NHK cells, as analyzed with annexin-V/propidium iodide (PI) staining using flow cytometry.
doi:10.1371/journal.pone.0146654.g002
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To analyze the effect of 2DG on cell proliferation and apoptosis we incubated primary renal
tubular epithelial cells from Cy/+ rats with increasing concentrations of 2DG and found
reduced cellular growth, as measured by the MTS assay (IC50 = 5.1 mM, Fig 2C). We also eval-
uated the effect of 2DG on cell proliferation and apoptosis of primary cultures of human
ADPKD cells and control NHK cells. Incubation with 2DG limited cell proliferation (BrdU
assay) and increased apoptosis (annexin-V staining) of primary human ADPKD cells in con-
centration-dependent manner (Fig 2F and 2G). Of note, the effects of 2DG on cell proliferation
and apoptosis were more pronounced on ADPKD cells than on NHK cells, indicating a thera-
peutic potential of 2DG in human ADPKD (Fig 2F and 2G).
In vivo effect of 2DG treatment
Effect of 2DG treatment on kidney weight and morphology. To assess the in vivo effect
of glycolysis inhibition on cyst development and disease progression, we examined the effects
of 2DG treatment in Han:SPRD Cy/+ and +/+ control rats. Rats were treated with 500 mg/kg/
day 2DG or vehicle NaCl daily for 5 weeks. Based on the human equivalent dose [16], the
amount of 2DG administered is equivalent to approximately 81 mg/kg/day in human. A previ-
ous study has reported 63 mg/kg/day to be the clinically tolerable dose for human clinical trials,
with reversible side effects observed at a dose range of 63–88 mg/kg/day [17]. The dose used in
the current proof-of-concept study should therefore not lead to any significant irreversible
adverse effects.
The 5-week treatment with 2DG was generally well tolerated in both animal groups. Side
effects included lower body weight and mildly increased diuresis in 2DG-treated Cy/+ and
+/+ rats. There were no significant changes in the plasma Na+ and Cl−, and no difference in
plasma glucose levels between 2DG- and vehicle-treated Cy/+ and +/+ rats. At the end of the
5-week treatment phase, the total weight of both kidneys was significantly lower in 2DG-
treated Cy/+ rats in comparison with vehicle-treated Cy/+ rats (-27.2%, P< 0.001; Table 1). The
2-kidneys/body weight ratio was also lower upon 2DG treatment in Cy/+ rats as compared to
vehicle treatment (-20.4%, P< 0.01; Table 1, Fig 3A and 3B).
Table 1. Effect of 2DG treatment on kidney and body weight.
+/+ Cy/+
Baseline Week 2.5 Week 5 Baseline Week 2.5 Week 5
Vehicle 2DG Vehicle 2DG Vehicle 2DG Vehicle 2DG
Number of
animals (n)
20 10 10 10 10 20 10 10 10 10
Age (in weeks) 5 7.5 7.5 10 10 7.5 7.5 10 10
Body Weight (g) 161.4
(17.5)
284.7
(17.9)
266.8
(25.5)
339.2
(28.2)
328
(24.6)
167.4
(20.0)
290.1
(33.2)
263.1
(25.3)
345.0
(31.5)
317.1*
(26.0)
Total kidney
weight (g)
2.38
(2.66)
2.35
(1.75)
8.67
(1.46)
6.31***
(1.14)
%TKW/BW 0.70
(0.06)
0.72
(0.04)
2.50
(0.29)
1.99**
(0.30)
Data are presented as means and standard deviations (in parentheses).
*P<0.05,
**P<0.01,
***P<0.001 when comparing 2DG- versus vehicle-treated groups at each time point. TKW/BW, total kidney weight divided by body weight.
doi:10.1371/journal.pone.0146654.t001
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Histomorphological examination of the kidney sections showed that vehicle-treated Cy/
+ rats had enlarged kidneys with multiple cysts which were not present in +/+ rats, as expected
(Fig 3A). Treatment with 2DG resulted in a reduced size of the kidneys and reduced cyst sizes
in Cy/+ rats compared with vehicle treatment (Fig 3A). Furthermore, quantification of the
number of cysts on periodic acid Schiff-stained sections showed a significant reduction of the
cyst index in 2DG-treated Cy/+ rats as compared to vehicle treatment (Fig 3C). Frequency dis-
tribution analysis of the cyst size showed that treatment with 2DG led to a shift in the size pro-
file of the cysts (Fig 3D). The total number of cysts was similar in 2DG- and vehicle-treated
rats (Fig 3E), suggesting that 2DG treatment affected cyst growth rather than cyst development
in Cy/+ rats.
Effect of 2DG treatment on renal function. We then evaluated the effects of 2DG treat-
ment on the parameters of renal function. Cy/+ rats developed significant impairment of renal
function as compared to +/+ rats (Fig 4A, 4B and 4C). Following treatment with 2DG, Cy/
Fig 3. Effect of 2DG treatment on kidney weight and morphology in Han:SPRD Cy/+ rats. (A) Representative images of periodic acid-Schiff staining of
kidneys from 10 week old +/+ and Cy/+ rats after 5-week treatment with 2DG or vehicle. (B) Ratio of total kidney weight (TKW) to body weight (BW) in 10
week old Cy/+ rats after 5-week treatment with 2DG or vehicle. (C). Cyst index in kidneys from Cy/+ rats after 5-week treatment with 2DG or vehicle. (D)
Frequency distribution of the cyst size, and (E) total number of cysts, in kidneys from Cy/+ rats following 5-week treatment with 2DG or vehicle.
doi:10.1371/journal.pone.0146654.g003
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+ rats had lower plasma creatinine levels as compared to vehicle treatment, with significantly
higher clearances for creatinine (Fig 4A), BUN (Fig 4B) and uric acid (Fig 4C). Furthermore,
the albumin excretion following treatment with 2DG was significantly lower as compared to
vehicle-treated Cy/+ rats (Fig 4D and 4E). Lactate content in the kidneys of vehicle-treated Cy/
+ rats were significantly higher than in vehicle-treated +/+ rats (Fig 4F). Treatment with 2DG
reduced the level of lactate in the kidneys of Cy/+ rats when compared to vehicle treatment
(Fig 4F).
Effect of 2DG treatment on cell proliferation and apoptosis. To examine whether 2DG
reduces cyst epithelial cell proliferation we stained kidney sections for Ki67 and found a
marked reduction in Ki67-positive nuclei in the tubular epithelium of Cy/+ kidneys as com-
pared to vehicle treatment (Fig 5A and 5B). We also tested for apoptosis, examining active cas-
pase-3 expression by Western blot analysis of kidney tissues from the Cy/+ rats. We found no
difference in the level of active caspase-3 expression after treatment with 2DG as compared to
vehicle treatment (Fig 5C). These data suggest that 2DG limits cyst growth in Cy/+ rats by
inhibiting cell proliferation rather than by promoting apoptosis in the cystic epithelium.
Effect of 2DG treatment on cellular signaling pathways. To further characterize the
mechanisms of the increased glycolysis observed in Han:SPRD rats, we assessed the effect of
2DG on important signaling pathways that have previously been shown to be dysregulated in
ADPKD. First, we examined the effect of 2DG on the phosphorylation of AMPK-α, an impor-
tant negative regulator of mTOR, which has been shown to be reduced in PKD.
Fig 4. Effect of 2DG treatment on parameters of renal function. Measurement of (A) creatinine clearance, (B) BUN clearance, and (C) uric acid
clearance, in +/+ and Cy/+ rats upon treatment with 2DG or vehicle at baseline, 2.5 weeks and 5 weeks. Black, +/+ treated with vehicle; blue, +/+ treated with
2DG; red, Cy/+ treated with vehicle; green, Cy/+ treated with 2DG. *P<0.05, **P<0.01 when comparing Cy/+ 2DG and Cy/+ vehicle at each time point.
#P<0.05, # # P<0.01 when comparing Cy/+ and +/+ group. (D) Urine albumin excretion in Cy/+ and +/+ rats after 5-week treatment with 2DG or vehicle. (E)
SDS-polyacrylamide gel electrophoresis of urine samples from Cy/+ and +/+ rats after 5-week treatment with 2DG or vehicle. (F) Lactate content in the
kidneys of Cy/+ and +/+ rats after treatment with 2DG or vehicle.
doi:10.1371/journal.pone.0146654.g004
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Phosphorylation of AMPK-α was reduced in the kidney lysate from Cy/+ rats as compared to
+/+ rats. Treatment with 2DG significantly increased AMPK-α phosphorylation in the kidneys
of Cy/+ rats (Fig 6A). Next, we studied the effect of 2DG on the phosphorylation of two key
kinases previously known to be activated in PKD, i.e. extracellular signal-regulated kinase
(ERK; mitogen-activated protein kinase [MAPK] pathway) and p70 S6K (mTOR pathway). As
shown in Fig 6B and 6C, phosphorylation of both ERK and p70 S6K were increased in the kid-
ney of Cy/+ rats as compared to +/+ rats. Treatment with 2DG led to a significant reduction in
the phosphorylation of ERK (Fig 6B), but there was no effect on the phosphorylation of p70
S6K (Fig 6C). Interestingly, 2DG treatment led to increased Akt phosphorylation (Fig 6D),
which may likely explain the lack of an observable effect on p70 S6K as activation of Akt is
known to counteract the effect of increased AMPK phosphorylation on p70 S6K activation.
Fig 5. Effect of 2DG treatment on cell proliferation and apoptosis in Han:SPRD Cy/+ rats. (A) Representative images of Ki67 staining of cyst-lining
epithelium in kidneys of Cy/+ rats treated with 2DG or vehicle. (B) Quantification of Ki67-positive nuclei in kidneys of Cy/+ rats after 5-week treatment with
2DG or vehicle. (C) Western blot analysis of active caspase-3 in kidneys from Cy/+ rats after treatment with 2DG or vehicle.
doi:10.1371/journal.pone.0146654.g005
Fig 6. Effect of 2DG treatment on cellular signaling pathways in vivo. Measurements of phosphorylation levels of (A) AMPK, (B) ERK, (C) S6K, and (D)
Akt using Western blot analysis in the kidneys of 10 week old +/+ and Cy/+ rats following 5-week treatment with 2DG or vehicle.
doi:10.1371/journal.pone.0146654.g006
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Previous studies have shown that activation of mTOR signaling is connected to enhanced
glycolysis [18]. We therefore examined the effect of direct mTOR inhibition on the enhanced
glycolysis which we observed in primary human cell cultures of ADPKD cells. Treatment with
the mTOR inhibitor rapamycin (50 nM) reduced the enhanced mRNA expression of glycolytic
genes (Hk1, Hk2, Pkm2) in ADPKD cells and also reduced the enhanced levels of lactate in the
cell culture medium (Fig 7A–7D). In line with this, the expression of glycolytic genes and lac-
tate production was also inhibited with the AMPK agonist metformin (2 mM), further empha-
sizing the importance of mTOR in glycolysis regulation (Fig 7A–7D).
Discussion
In the present study we show that Han:SPRD Cy/+ rats display increased transcript levels for
glycolysis enzymes and decreased transcript levels for gluconeogenesis enzymes in the kidney.
Lactate and ATP levels were also increased in the kidneys and in TEC cultures of Cy/+ rats
compared to wild type +/+ kidneys. Similar findings were obtained in cultured TEC derived
from patients with ADPKD. Importantly, administration of 2DG, a glycolytic inhibitor,
retarded cyst progression, improved renal function in Han:SPRD Cy/+ rats and was associated
with reduced intrarenal lactate levels and normalization of altered signaling pathways. Taken
together our data suggest that in PKD there is metabolic reprogramming towards enhanced
aerobic glycolysis, a phenomenon which is known as the Warburg effect, after its discoverer
Otto Warburg.
Recently, Rowe et al. reported that mutation of Pkd1 results in enhanced glycolysis in a
mouse model of PKD and in kidneys from patients with ADPKD [8,19]. Metabolomic profiling
of the cell culture medium of Pkd1-deficient mouse embryonic fibroblasts showed increased
glucose uptake and lactate production. The authors also found that treatment with 2DG
delayed cyst growth in two rapidly progressive mouse models of PKD. However, the duration
of the treatment with 2DG was extremely short (2 days), which does not account for the slowly
progressive nature of the disease. In addition, the effect of 2DG on renal function could not be
assessed due to the rapidly progressive nature of the models. More recently, Chiaravalli et al.
used an orthologous and slowly progressive murine PKD model created by inducible inactiva-
tion of the Pkd1 gene postnatally and found that 2DG also had beneficial effects on cyst growth
at a lower dose (100 mg/kg for 5 days per week for 2 months) [20].
Increased glycolysis has been previously reported in proliferating cells which require altered
metabolism to efficiently incorporate nutrients such as glucose into biomass. Cancer cells, for
instance, primarily metabolize glucose by glycolysis, whereas most normal cells completely
catabolize glucose by oxidative phosphorylation [21]. This shift to aerobic glycolysis with
increased lactate production, coupled with increased glucose uptake, is likely used by prolifer-
ating cells to promote the efficient conversion of glucose into the macromolecules needed to
construct a new cell [22].
It has been shown that the Warburg effect is associated with defective mitochondrial respi-
ration in the context of a hypoxic environment [23]. Similar to cancer cells, cyst epithelial cells
in polycystic kidney disease are exposed to hypoxia and display mitochondrial dysfunction
[24,25,26,27]. Furthermore it has been shown that cyst epithelial cells display a high rate of
apoptosis, a process which is tightly regulated at the level of mitochondria [28]. Increased apo-
ptosis in polycystic Han:SPRD rat kidneys was shown to be due to the activation of caspase-3
and dysregulation of the balance between pro- and anti-apoptotic Bcl-2 family members, spe-
cifically a down-regulation of anti-apoptotic Bcl-XL [29]. Zamzami et al. have shown that apo-
ptosis is closely related to mitochondrial impairment [30]. There is also a high level of
mitochondrial DNA (mtDNA) damage in apoptotic cells [31]. It is therefore conceivable that
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damage to the mtDNA would cause malfunction in the respiratory chain in PKD, forcing the
cyst epithelial cells to use the aerobic glycolysis pathway to generate ATP.
The glucose analog 2-deoxyglucose (2DG) acts as a competitive inhibitor of glucose metabo-
lism.[32] Upon transport into the cells, 2DG is phosphorylated by hexokinase to 2DG-P. How-
ever, unlike G-6-P, 2DG-P cannot be further metabolized by phosphohexose isomerase, which
converts G-6-P to fructose-6-phosphate [33]. Thus 2DG-P is trapped and accumulates in the
Fig 7. Effect of selected inhibitors on the glycolysis pathway in vitro. Real-time quantitative PCR analysis of the genes coding for glycolytic enzymes (A)
Hk1, (B) Hk2, and (C) Pkm2 in primary cell cultures of human ADPKD cells following incubation with rapamycin (50 nM) or metformin (2 mM). (D) Lactate
production in the supernatant of NHK and ADPKD cells, and response to inhibitors.
doi:10.1371/journal.pone.0146654.g007
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cells, leading to inhibition of glycolysis mainly at the step of phosphorylation of glucose by
hexokinase. Inhibition of this rate-limiting step by 2DG causes a depletion of cellular ATP,
leading to blockage of cell cycle progression and cell death in vitro [34]. The anti-tumor effect
of 2DG has been well characterized in animal models and human clinical trials [35,36,37]. The
feasibility of using a glycolytic inhibitor in a defined and progressive rat model of PKD has not
been tested yet. In the current study, we investigated the therapeutic potential of 2-deoxyglu-
cose (2DG) in Han:SPRD Cy/+ rats, a well-known animal model of PKD which develop slowly
progressing renal cysts resembling human ADPKD.
A major complication of polycystic kidney disease is the deterioration of renal function.
Glomerular filtration rate (GFR) significantly decreases towards the later stage of the disease,
requiring the patients to initiate renal replacement therapy. Delaying the loss of renal function
has therefore been a major therapeutic aim in PKD. In our study we show for the first time that
2DG improved different parameters of renal function (clearances for creatinine, BUN and uric
acid). 2DG also ameliorated albuminuria, a common biomarker of altered and progressively
deteriorating renal function in PKD. Taken together our data suggest that 2DG or related mol-
ecules may have a beneficial therapeutic potential for patients with ADPKD.
Interestingly, we observed that either direct inhibition of mTOR signaling using rapamycin
or indirect inhibition using the AMPK agonist metformin reversed the glycolytic phenotype in
ADPKD cells in vitro. Furthermore, we found that phosphorylation of ERK1/2 was signifi-
cantly reduced in Cy/+ upon treatment with 2DG, which likely explains the observed effect of
2DG on cell proliferation. Interestingly, treatment of 2DG did not affect the phosphorylation
status of S6K which is highly enhanced in Cy/+ kidneys as compared to wild-type rats. This
could be explained by 2DG-mediated activation of the survival signal PI3K/Akt pathway,
which counteracts the effect of 2DG via ERK and AMPK. As previously described, mTOR
functions as a central node in a complex net of signaling pathways; it integrates signals from
the Akt, ERK, and AMPK pathways and plays an important role in regulating protein biosyn-
thesis, cellular growth, and proliferation [38,39]. Fig 8 summarizes the various signaling
Fig 8. Schematic diagram showing the interplay of various signaling pathways involved in the regulation of glycolysis in polycystic kidney
disease.
doi:10.1371/journal.pone.0146654.g008
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pathways involved in the regulation of glycolysis in ADPKD that have been investigated in this
study.
Taken together, our results show that the cystic kidneys of Han:SPRD Cy/+ rats display
enhanced aerobic glycolysis which likely plays an important role in the pathogenesis of PKD.
The administration of 2DG, a potent glycolytic inhibitor, markedly delayed the loss of renal
function and retarded cyst development Han:SPRD Cy/+ rats with PKD. Targeting the glyco-
lytic pathway may therefore present a novel therapeutic strategy to control cyst growth in poly-
cystic kidney disease.
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 Abstract 
 
A novel kidney imaging classification and estimated glomerular filtration rate (eGFR) 
prediction model for patients with autosomal dominant polycystic kidney disease 
(ADPKD) was recently proposed by the Mayo Clinic (Irazabal M. et al., J Am Soc 
Nephrol 2015; 26: 160-172). This classification and prediction model has 
demonstrated an accurate eGFR prediction for the American population. The 
objective of this study was to apply this same imaging classification to test the Mayo 
Clinic prediction model in a Swiss cohort of 203 ADPKD patients that had clinical 
follow-up data for up to 10 years. The eGFR prediction model showed an accurate 
correlation with the observed eGFR in Swiss ADPKD patients for up to 5 years of 
follow-up, but tended to underestimate observed eGFR values beyond 5 years, 
particularly in patients with less severe disease. In summary, our study shows that 
the Mayo Clinic prediction model appropriately predicts the eGFR decline in the short 
term in Swiss patients with ADPKD. 
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 Introduction 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common form 
of cystic renal diseases. With an incidence of 1:400 to 1:1.000, ADPKD it is one of 
the leading causes of end-stage renal disease (ESRD) in adults and affects all ethnic 
groups worldwide [1,2]. An early and accurate prediction of chronic kidney disease 
(CKD) progression may help to develop more efficient strategies to confront the 
disease and the progression to ESRD [3]. 
 
Recently, a prediction model for eGFR decline in ADPKD has been developed at the 
Mayo Clinic by Irazabal et al. [4]. The model uses the parameters age, sex and 
height-adjusted total kidney volume at baseline (hTKV0) to predict eGFR decline over 
time in a longitudinal mixed-effects regression equation. The model was derived from 
two different ADPKD populations in the United States, the Consortium for Radiologic 
Imaging Study of PKD (CRISP) and the Mayo Clinic Translational Polycystic Kidney 
Disease Center (MTPC) cohorts. In the present study, we tested whether this 
longitudinal mixed-effects regression model also correctly predicts the eGFR decline 
in a cohort of Swiss ADPKD patients. 
 
Materials and methods 
Patients 
 
The clinical data from well-characterized patients with ADPKD from the University 
Hospital in Zürich, Switzerland, were used in this study. All participants gave their 
written informed consent. Patients younger than 20 years were excluded since eGFR 
estimation equations tend to be unreliable in these patients [5,6]. Baseline data 
included age, gender, body height, magnetic resonance imaging-based total kidney 
volume (TKV) and serum creatinine. The eGFR was calculated according to the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Patients 
had yearly follow-up visits for creatinine/eGFR determinations for up to 10 years. 
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 Classification of patients into classes 1A, 1B, 1C, 1D and 1E 
 
Based on the radiological classification as proposed by M. Irazabal et al. [4] we 
selected 203 ADPKD patients with class 1 (typical) ADPKD, and excluding the class 
2 (atypical) cases. The class 1 patients were then stratified into 5 subclasses (1A to 
1E) of ADPKD according to the estimated yearly hTKV growth rates: <1.5% (1A), 1.5-
3.0% (1B), 3.0-4.5% (1C), 4.5-6.0 (1D) and >6.0% (1E). 
 
eGFR prediction equation 
 
Irazabal et al. developed and reported to us (personal communication) their 
longitudinal mixed-effects regression equation [4]. This formula is based on the age, 
sex and height-adjusted total kidney volume at baseline (hTKV0) and includes the 
patients’ classification in subclasses (1A-1E). 
 
A prototype software application was developed to analyze the patients’ data from a 
single database. This software compiles date of birth, date of visit, gender, height and 
blood creatinine measurements and reports the eGFR estimation using the 
longitudinal mixed-effect prediction equation. The class ranges were computed by 
fitting the hTKV at baseline into the ranges defined by log (hTKVn/hTKVn-1) limits 
between classes (A<1.5, B<3.0, C<4.5, D<6.0, E>6.0). 
 
Statistical analyses 
 
Quantitative variables are described as means ± SD. Correlation by linear regression 
and Bland-Altmann analyses were used to show the relationship between predicted 
eGFR and observed eGFR. A P<0.05 was considered statistically significant. 
GraphPad Prism version 5.0 software (GraphPad, San Diego, CA, USA) was used 
for data analysis. 
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 Results 
Baseline data of Swiss ADPKD patients 
 
All class 1 ADPKD patients were subdivided into the classes 1A to 1E according to 
their age and their hTKV0 at baseline. Table 1 shows the baseline data of the 
patients, stratified according to the classes 1A to 1E. From the total of 203 included 
patients, 13% were classified in class 1A, 29% in class 1B, 31% in class 1C, 20% in 
class 1D and 8% in class 1E. The percentage of males increased from the least 
pronounced class 1A (34.6%) to the most severe class 1E (81.3%). Mean age (35 ± 
10 years) and height (175 ± 9 cm) did not show significant differences among the 
classes. The eGFR declined from class 1A to class 1E, whereas the hTKV increased, 
as expected. The distribution of patients by age and hTKV according to the classes 
1A to 1E is graphically presented in Figure 1. 
 
Predicted and observed eGFR decline 
 
Based on the baseline data we calculated the predicted eGFR decline in the different 
classes 1A to 1E of the 203 Swiss ADPKD patients. As shown in Figure 2A, the 
predicted eGFR decline differed significantly among the different subclasses. Next, 
we analyzed the decline of the observed eGFR in the different classes (Figure 2B). 
Again we found that the observed eGFR decline differed significantly among the 
different classes. Thus, in a first approximation we found that the longitudinal mixed-
effects equation generated predicted eGFR values which paralleled the observed 
eGFR decline. 
 
Correlation between predicted and observed eGFR decline 
 
When we correlated the predicted with the observed eGFR decline according to the 
longitudinal mixed-effects regression equation, we observed a strong overall 
correlation (r=0.884, R2=0.781) (Figure 3A). When classes were analyzed separately, 
the classes 1B, 1C, 1D and 1E showed a strong correlation (R2>0.7, p<0.0001), 
whereas class 1A showed only a weak but still significant correlation (R2=0.518, 
p<0.0001) (Table 2). Figure 3B shows the Bland-Altman analysis where dots 
represent the difference between predicted and observed values of individual 
101
 patients. This analysis show a tendency to underestimate the observed eGFR, 
especially in patients with higher eGFR values (>60 ml/min/1.73 m2). 
 
Accuracy of eGFR prediction over time 
 
To analyze the precision of the prediction model over time we calculated the 
observed and the predicted eGFR for each year of follow-up, up to a maximum of 10 
years. Figure 4 shows the differences between observed eGFR and predicted eGFR 
in the different classes along 10 years of follow-up. During the first 5 years of follow 
up, the predicted eGFR closely matched the observed eGFR in all classes (maximum 
mean difference of  -7.9 ± 15.6 ml/min/1.73 m2 in class 1A). Beyond 5 years, the 
prediction tended to slightly underestimate the observed eGFR in classes 1A, 1C and 
1E (maximum mean difference of -19.0 ± 11.5 ml/min/1.73 m2 in class 1A). 
 
Discussion 
Formulas which predict the decline in eGFR are of great importance to counsel 
patients with various diseases that cause CKD [7,8]. Long term prediction equations 
may serve as useful tools to identify patients at risk for progression and to define 
optimal treatment in individual patients. Consequently, there is an increased demand 
of accurate prediction models for the different patient populations. As demonstrated 
by Tangri et al. [9], estimations based exclusively on creatinine are not sufficient to 
correctly predict kidney function. The inclusion of more classification parameters 
which can easily be obtained, such as different laboratory tests, may result in more 
accurate prediction models. In the case of ADPKD, the TKV in combination with age 
proved to be the most powerful parameters for predicting kidney function decline [10-
13]. 
 
In this study, the novel longitudinal mixed-effects equation proposed by M. Irazabal et 
al. was tested in a population of ADPKD patients from the University Hospital in 
Zürich. This novel prediction equation uses age, sex and hTKV at baseline to predict 
kidney function decline. Irazabal and colleagues determined the TKV by ellipsoid 
equation, with the limitation that there is a certain imprecision in comparison with the 
stereological method for TKV determination. However, the two volume 
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 measurements seem to correlate quite well [14,15]. Our TKV values were based on 
the stereological method, and are therefore very precise [16,17]. 
 
The Mayo Clinic model as developed by Irazabel et al. was less accurate in ADPKD 
patients with close to normal kidney function. In addition, some patients may change 
to a more severe class and should be reevaluated. Only 3.7% of the Swiss patients 
changed to a worse subclass during the follow up (data not shown). Our analysis in 
the Swiss population shows that the overall predicted eGFR correlates well with the 
observed eGFR. However, our data of the predicted eGFR over 10 years reveal a 
tendency to underestimate the observed eGFR when the prediction time is beyond 5 
years. This was most pronounced in patients with better renal function (eGFR>60 
ml/min/1.73 m2). A clear limitation of this study resides in the number of patients 
included, especially for subclass 1E. Due to this limited sample size a larger cohort 
and a longer follow up may be required to clarify the magnitude of this effect. 
 
A novel model, the PROPKD score [18], was proposed to classify PKD patients 
according to their risk of kidney failure. This model uses genetic and clinical 
variables, including type of PKD mutation, hypertension before 35 years and first 
urologic event before 35 years of age to score patients into 3 different classes: low-
risk, intermediate-risk and high-risk of ESRD. The PROPKD score accurately predicts 
an evolution without ESRD before 60 years for patients in the low-risk category, with 
a negative predictive value (NPP) of 81.4%. The model was not found to be suitable 
for patients younger than 20 years old. A comparison of the Mayo and the PROPKD 
models [15] suggested that due to the cost and limited availability of genetic analysis, 
it would be difficult to implement the PROPKD model routinely at the present time, 
but it might become a helpful tool in the future. 
 
In summary, the new longitudinal mixed-effects equation predicts the eGFR decline 
with accuracy over a reasonable time period in ADPKD patients of the Swiss 
population. The eGFR in the subclasses 1C, 1D and 1E seemed to be predicted best 
by the mixed-effects equation, whereas the eGFR of patients in the subclasses 1A or 
1B could be predicted with much less precision. The inclusion of additional (yet to be 
defined) clinical or laboratory parameters to the Mayo model may improve the 
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 prediction of the critical groups and help to paint a better picture of ADPKD patient 
prognosis in the future. 
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 Tables 
 
 
 
 
 
 
 
Table 1: Basic characteristics of Swiss cohort of ADPKD patients organized by subclasses 
(1A to 1E). Data are derived from a total of 203 Swiss ADPKD patients. The eGFR is based 
on the CKD-EPI equation. Age, height, hTKV and eGFR are means ± SD. *Follow up are 
median (interquartile range). 
  
 ADPKD subclasses 
 1A 1B 1C 1D 1E All 
Patients (%)  26 (12.8%) 58 (28.6%) 63 (31.0%) 40 (19.7%) 16 (7.9%) 203 (100.0%) 
Sex (% males) 34.6% 41.4% 60.3% 75.0% 81.3% 56.2% 
Age (years) 30.0 ± 8.8 33.0 ± 9.3 34.0 ± 8.4 32.0 ± 7.9 26.0±7.0 34.8 ± 9.7 
Height (cm) 173.0 ± 7.2 174.0 ± 8.3 176.0 ± 9.9 177.0 ± 10.4 179.0 ± 6.2 174.9 ± 9.1 
hTKV (cm3/m) 207.0 ± 32.7 343.0 ± 92.8 546.0 ± 181.7 835.0 ± 404.7 1085.0±362.0 636.8 ± 455.3 
eGFR  
(ml/min/1.73 m2) 
98.8 ± 16.9 94.2 ± 19.7 91.4 ± 19.3 86.7 ± 19.7 85.6 ± 24.8 96.7 ± 38.3 
Follow up (years)* 4 (2-6) 4 (2-5) 3 (2-5) 5 (3-6) 4 (3-5) 4 (2-5) 
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Table 2 Correlation coefficients (r) and coefficients of determination (R2) between predicted 
and observed eGFR in the different subclasses (1A to 1E). 
  
 Subclasses 
 1A 1B 1C 1D 1E All 
Number of 
patients 
26 58 63 40 16 203 
r 0.720 0.895 0.887 0.873 0.865 0.884 
R2 0.518 0.800 0.791 0.763 0.748 0.781 
P value 
(two-tailed) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
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 Figures 
 
 
 
 
 
 
 
 
 
Figure 1: Classification of 203 Swiss ADPKD patients by age and TKV at baseline 
(hTKV0). The classes 1A to 1E are defined by their kidney growth rate ranges, i.e. 
<1.5% (1A), 1.5-3.0% (1B), 3.0-4.5% (1C), 4.5-6.0 (1D) and >6.0% (1E). 
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 Figure 2: Predicted and observed eGFR over time. A) Average predicted eGFR 
(ml/min per 1.73 m2) over time by subclasses. B) Average observed eGFR (ml/min 
per 1.73 m2) over time by subclasses. 
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Figure 3: Correlation between observed and predicted eGFR (ml/min per 1.73 m2). 
A) Linear correlation between observed and predicted eGFR. Black line represents 
the overall linear regression. Each dot represents an individual patient and is colored 
according to its class. B) Bland-Altman analysis of eGFR, showing differences 
between observed and predicted eGFR against the observed eGFR by CKD-EPI 
equation. Dotted lines means 95% limits of agreement 
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Figure 4: Differences between predicted and observed eGFR (ml/min per 1.73 m2) 
over time from a minimum of 1 year (n=203) to a maximum of 10 years (n=9) of 
follow-up. Data are means ± SD. Data points below 0 signify underestimated values, 
data points above 0 mean overestimated values. 
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Summarizing discussion 
Polycystic kidney disease is characterized by formation of multiple cysts throughout the 
kidney parenchyma. Two essential mechanisms play a key role in the disease progression: 
the proliferation of cystic epithelial cells and the cyst fluid secretion. Both processes lead to 
cyst expansion. Recent research efforts resulted in the discovery of many potential targets to 
limit cyst expansion. Various drugs were shown to ameliorate PKD progression, but an 
effective treatment to stop PKD disease progression has still not been identified. Glucose 
transport and metabolism emerges now as an innovative way to approach the disease. In 
this thesis we demonstrate that the inhibition of glucose transport or glucose metabolism 
both reduce cyst expansion and disease progression in animal models of PKD. Figure 8.1 
provides a scheme which depicts the essential steps in these pathways of glucose transport 
and metabolism and the interactions with intracellular signaling cascades. 
Figure 8.1: Glucose transport and metabolism in cyst epithelial cell. SGLT inhibitors (phlorizin, dapagliflozin) 
block glucose reabsorption in proximal tubules of nephrons, creating an osmotic gradient that forces the cyst fluid 
to reenter the tubular lumen, thereby reducing cyst expansion. Glucose analogs (2-deoxyglucose, 2DG) inhibit the 
enhanced aerobic glycolysis present in proliferative tissues of PKD. Additionally 2DG reduces ERK 
phosphorylation and stimulates AMPK phosphorylation, both inhibiting mTOR activity. Potential combination of 
SGLT inhibitors or 2DG with metformin or rapamycin may generate synergistic effects on cell proliferation. 
 
Non selective SGLT inhibition 
In Chapter 2, the dual inhibition of SGLT1 and SGLT2 with phlorizin was tested in 
Han:SPRD rats. Phlorizin exercises a specific and competitive inhibition of both SGLT1 and 
SGLT2 cotransporters without affecting GLUT transporters. We hypothesized that by 
inhibition of glucose transport through the epithelium, glucose concentration in the lumen of 
tubules may increase considerably and could create a gradient that forces fluid transfer from 
adjacent cysts to the lumen, ameliorating cyst expansion. In Han:SPRD rats, a model for 
ADPKD, we observed that chronic inhibition with phlorizin, a non selective SGLT inhibitor, 
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effectively caused glycosuria and osmotic diuresis. Although phlorizin did not completely stop 
disease progression, it improved renal function, albuminuria and reduced total kidney weight. 
Additionally, phlorizin decreased cell proliferation and inhibited the MAPK pathway. 
These experiments with phlorizin demonstrated that SGLT inhibition is a potential therapy 
that can reduce the disease progression and partially limit the decline in kidney function in 
experimental rats with PKD. Nevertheless, phlorizin presents several limitations. It is poorly 
absorbed orally since it reacts with hydrolytic enzymes and is then converted to phloretin in 
the small intestine. Thus it must be administrated via subcutaneous injections (1). Phlorizin is 
therefore not the best choice for a potential PKD treatment. 
As mentioned, phlorizin is a competitive inhibitor of both SGLT1 and SGLT2. Nevertheless, 
SGLT2 is responsible for the most of glucose reabsorption in the kidney (90%) while SGLT1 
only manages a small portion (10%). The specific inhibition of SGLT2 with a selective drug 
may therefore achieve a similar increase in the glucose concentration in the lumen. Based on 
the structure of phlorizin, several SGLT2-specific inhibitors have been developed (Table 8.1). 
Dapagliflozin (DAPA) is one of these specific SGLT2 inhibitors that has the advantage of 
being effectively absorbed by the enteral route. DAPA has been developed and marketed for 
the treatment of type 2 diabetes mellitus (2). Thus we tested DAPA in Han:SPRD rats and a 
second model (PCK rats) to examine whether it provided similar beneficial effects on PKD 
progression. In Chapter 3 and Chapter 4 we report the results from testing the effects of 
DAPA in Han:SPRD and PCK rats. 
Table 8.1: Potency and selectivity of diverse SGLT inhibitors. Data are shown as mean IC50 and pIC50. 
Abbreviations:  AMG, α-methyl glucose; SEM, standard error mean.  Table is from R. Rempler: Empagliflozin, a 
novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterization and comparison with other 
SGLT-2 inhibitors. Diabetes, Obesity and Metabolism 14: 83–90, 2012.  
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Selective SGLT2 inhibition 
In Chapter 3 we tested whether DAPA can stimulate a similar osmotic diuresis, thereby also 
reducing cyst expansion in Han:SPRD rats, a rat model of PKD that phenotypically 
resembles human ADPKD. In contrast to phlorizin, DAPA is well absorbed orally, thus rats 
received daily oral doses during 5 weeks. 
Compared with phlorizin, DAPA treatment resulted in a lesser increase of glucosuria and 
osmotic diuresis. Thus glucosuria (18.0±4.6 PHLO vs. 15.8±4.5 mmol/day DAPA) and 
diuresis (65.0±2.2 PHLO vs. 42.7±7.0 ml/day DAPA) increased less in DAPA-treated 
Han:SPRD. Surprisingly, DAPA increased the kidney mass in Han:SPRD, an effect that was 
also seen in normal rats treated with DAPA. These hypertrophic effects of DAPA seemed not 
to be associated with an increased severity of the cystic disease, since no differences in cyst 
index or cyst number were observed between groups. Histological analyses for cell 
proliferation, macrophages infiltration and interstitial fibrosis did not reveal significant 
differences when DAPA- and vehicle-treated Han:SPRD rats were compared. 
Several studies have described the apparently reduced effect of selective SGLT2 inhibitors 
over dual SGLT1/2 inhibitors in animal and humans (3-5). Abdul-Ghani et al. (6) suggested 
that when SGLT2 is inhibited, SGLT1 can increase its glucose absorption activity (Figure 
8.12). SGLT1 is located more distally in the S3 segment of proximal tubules. Due to the main 
absorption of glucose by SGLT2 in the S1 segment, SGLT1 normally operates at 
submaximal transport capacity but with inhibition or absence of SGLT2, SGLT1 is forced to 
reach full capacity. In consequence, the total amount of glucose absorbed in the kidney is 
greater than expected with SGLT2 inhibition. It appears therefore that the potential effect of 
DAPA on SGLT2 is blunted by compensatory SGLT1 activity. 
Figure 8.2: Selective inhibition of SGLT2 cotrantsporter in the S1 segment stimulates compensatory glucose 
reabsorption via SGLT1 in the S3 segment of the proximal tubule. Figure is from Muhammad A. Abdul-Ghani, 
Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. 
Diabetes 62:3324–3328, 2013. 
How DAPA increases the kidney mass without affecting cyst expansion or proliferation 
remains unclear. Such a hypertrophic effect was also seen in SGLT2 knock-out mice (7). In 
addition, a hypertrophic response was also noticed in SGLT1-overexpressing 
cardiomyocytes (8). Likewise the increased activity of SGLT1 may stimulate a hypertrophic 
response in the tubular epithelial cells of the S3 segment during inhibition of SGLT2, 
resulting in an increase of the total kidney mass. 
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The lack of a significant effect of DAPA on cell proliferation, macrophage infiltration and 
interstitial fibrosis is in contrast to the effects of phlorizin which was demonstrated to have an 
effect on proliferation via direct inhibition of ERK1/2 phosphorylation. This effect might be 
exclusive to phlorizin and is probably not related to the osmotic diuresis caused by SGLT 
inhibition. Whether more potent dual SGLT inhibitors can also inhibit cell proliferation via 
MAPK pathway remains to be studied. 
In Chapter 4 we describe the effect of DAPA in PCK rats, an animal model of ARPKD. Daily 
doses of DAPA were administered orally over a period of 6 weeks. Dapa effectively caused 
osmotic diuresis and glycosuria in PCK rats exceeding values obtained with DAPA in 
Han:SPRD (23.6±4.3 mmol/day of urine glucose and 57±7 ml/day of diuresis). However, 
kidney function deteriorated more rapidly with DAPA in PCK rats, and lead to a marked 
increase in cyst size. Using a new imaging technology (high resolution ultrasound) we could 
accurately measure kidney and cyst volume in vivo. The details of this new approach are 
described in Chapter 5. Unexpectedly, DAPA-treated kidneys showed 2-fold bigger cysts 
than vehicle-treated kidneys. There was no difference in the number of cysts between DAPA- 
and vehicle-treated kidneys. The total kidney weight and the cyst index increased 
significantly under DAPA treatment. In contrast with this increased cyst burden, DAPA did 
not lead to significantly increased intrarenal cAMP levels or enhanced cyst epithelial cell 
proliferation. 
The PCK model is characterized by the development of multiple large cysts in the medullary 
area of the kidney. Cysts are originating from the collecting duct and most of them remain 
connected to the tubular lumen (9). This permanent connection could play a key role in the 
cyst-expanding effect of DAPA. The osmotic pressure in the collecting duct may force fluid to 
enter the cysts and increase their size. In agreement with this hypothesis, several studies 
have demonstrated a relationship between luminal pressure and proliferation of intestinal 
epithelial cells (10, 11). Likewise, the osmotic pressure may be responsible for cyst 
expansion in DAPA-treated PCK rats. 
Taking it together, the results exposed in Chapters 2, 3 and 4 demonstrate that SGLT 
inhibition cannot effectively stop or reverse cyst progression in rat models of PKD. However, 
it opens a new way to explore the pathogenesis of the disease. Currently, many others SGLT 
inhibitors are being developed (12-15) and it appears that less selective SGLT2 inhibitors 
with a strong inhibition of SGLT2 and partial inhibition of SGLT1 might be most effective. 
Sotagliflozin (16, 17) is a non-selective SGLT inhibitor currently in phase 3 for treatment of 
type 1 diabetes mellitus. More potent than phlorizin, sotagliflozin is well tolerated orally and 
might become a promising drug for PKD, potentially in combination with drugs that also 
target cyst proliferation like metformin or rapamycin. 
 
  
118
 Aerobic glycolysis inhibition by 2 deoxyglucose 
As explained in Chapter 1, cancer and proliferative tissues show an increased aerobic 
glycolysis, a phenomenon known as Warburg effect (18). This enhanced aerobic glycolysis, 
observed in proliferative ADPKD tissues by Rowe et al. (19), offers a unique chance to 
achieve therapeutic selectivity in PKD. In the same study, they demonstrated efficacy of 2-
deoxyglucose (2DG), an analogue of glucose, blocking glycolysis and inhibiting cyst growth 
in mouse models. In Chapter 6 we have expanded the previous observations and tested 
whether 2DG is effective in the Han:SPRD rat model of PKD. 
We observed at the mRNA level that glycolysis was indeed increased while gluconeogenesis 
was decreased in cystic kidneys of Han:SPRD rats. After treatment with daily subcutaneous 
injections of 2DG over 5 weeks, the production of lactate derived from aerobic glycolysis 
decreased significantly in Cy/+ rats. Significant reductions of kidney weight and cyst index 
were also noticed. 2DG-treated rats also showed improved kidney function, with increased 
creatinine and BUN clearances. Furthermore, 2DG reduced cyst epithelial cell proliferation in 
Cy/+ kidneys while apoptosis was not affected. Attending to the pathways involved that had 
been demonstrated to be enhanced in Cy/+ rats, 2DG enhanced the phosphorylation of 
AMPK (which is reduced in untreated Cy/+). Additionally, 2DG reduced significantly the 
phosphorylation of ERK (MAPK pathway) but increase the phosphorylation of Akt (mTOR 
pathway). 
These results demonstrate that the Warburg effect phenomenon is actively taking place in 
PKD animal models and can be targeted by analogues of glucose that block the enhanced 
glycolysis. 2DG effectively delayed the loss of kidney function and cyst progression in the 
Han:SPRD rat model. Nevertheless, the 2DG-induced activation of Akt may have 
counteracting effects since Akt phosphorylation promotes cell survival via apoptosis inhibition 
(20, 21). 
A combination treatment of 2DG and metformin was reported to have significant synergistic 
apoptotic effects on a variety of cancer types in vitro (22, 23). Interestingly, 2DG/metformin 
combined treatment leads to an increase in caspase-3 activity which stimulates apoptosis in 
cancer cells. Thus, the potential of combination therapy with 2DG and metformin or 
rapamycin should be tested in further experiments. 
ADPKD patient classification and prediction of kidney function 
Our studies on glucose transport and metabolism may have a potential application in the 
treatment of patients with ADPKD. During development of clinical studies, the use of well 
defined inclusion criteria and an accurate measurement of critical progression parameters 
are fundamental. In particular the estimated glomerular filtration rate (eGFR) and the 
prediction of its course over time is a powerful tool that offers investigators an accurate 
estimation of the decline in kidney function (24, 25). Through Chapter 7 we tested the 
applicability of a novel longitudinal mixed-effects equation to predict the eGFR decline over 
10 years of follow up of Swiss ADPKD patients. By classifying patients within the different 
subclasses of ADPKD according their height-normalized total kidney volume (hTKV), an 
accurate prediction of the eGFR decline during the first 5 years was possible. However we 
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found that there was a tendency to underestimate the observed eGFR in the long-term, and 
this was most pronounced in patients with preserved renal function (i.e. an eGFR >60 
ml/min/1.73 m2). Our data suggest that the longitudinal mixed-effects equation is a useful tool 
for eGFR prediction, especially when it is lower than 60 ml/min/1.73 m2. Furthermore, our 
study suggests that the severe subclasses (1D and 1E) might benefit most from future 
treatments. These patients should therefore be considered for inclusion in future studies. 
 
Concluding remarks 
The transport and metabolism of glucose opens a new branch of opportunities to treat PKD. 
The advances in developing dual SGLT inhibitors which can generate a strong inhibition of 
SGLT2 and partial inhibition of SGLT1 could be used to achieve similar benefits which were 
observed with phlorizin. Furthermore, the existence of an enhanced glycolysis in PKD cells 
provides another opportunity to target the disease. 
Together with novel drugs that target the affected signaling pathways, SGLT inhibitors and 
2DG may improve the effectiveness of the treatments of PKD. Thus it seems that we may be 
a step closer in the long way of finding a cure for PKD. 
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